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1. INTRODUCTION 
The increasing burden of cancer is widely recognized around the world. The 
main reason for the increase is considered to be the trend of a growing pro-
portion of advanced aged people who are more vulnerable to cancer (Thun et 
al., 2010). The control of infectious and cardiovascular diseases in conjunction 
with an improving economic background has led to the increasing burden of 
cancer (Ginsburg et al., 2017). The knowledge of cancer development and 
behavior are comprehensively studied from observational studies of molecular 
characteristics (Hanahan et al., 2011) and cancer treatment has evolved rapidly 
over the past decades. Despite new technologies and advanced therapies, the 
deaths due to cancer have become the second cause of death after cardio-
vascular diseases in developed countries (WHO, 2019). In the majority of 
highly developed countries, cancer has become the main cause of premature 
deaths (age 0–69), while it ranks second in the Baltic countries and most 
Eastern European countries (Ferlay et al., 2018). Women contribute approxi-
mately 49% of the world population but more than 60% of people over 60 years 
(Population Reference Bureau, 2019). The rising cancer incidence among 
women is recognized in recent years (Ginsburg et al., 2017). The cancer 
incidence among young women aged 20–49 is estimated to be far higher than 
among men at that age (Ward et al., 2019). Women’s cancer related premature 
deaths and disability have a strong impact on world cancer control efforts today. 
The socioeconomic disparities and rising cancer incidence among women have 
been brought out both in high- and low-income countries (Ginsburg et al., 
2017). 
Gynecological cancers comprise approximately 15% of all female malignant 
tumors in Europe (Ferlay et al., 2018; Ferlay et al., 2015) in 2018 and 13% of 
all female cancers in Estonia in 2016 (National Institute for Health Develop-
ment, 2019). Uncontrolled growth of abnormal cells as cancer that develop from 
female genital organs have different patterns of growth and spread. Cancers of 
the ovaries, uterus, uterine cervix, fallopian tube, vagina and vulva are a hetero-
geneous group of malignant tumors that have distinct etiological factors, pre-
ventive and therapeutic approaches. The incidence rates of gynecological 
cancers have different long term trends that are found to be influenced by 
several societal, economic and health care factors like dietary intake and phy-
sical activity, sexual behavior and birth-control approaches (Hüsing et al., 2016; 
Nagle et al., 2018). In countries with well-organized cervical cancer screening 
programs the continuous decrease of cervical cancer incidence is detected 
(Vaccarella et al., 2013). The introduction of oral contraceptives in the 1960s is 
found to be related to the continuous decrease of ovarian cancer incidence 
(Sopik et al., 2015). Increasing prevalence of obesity is the main cause of the 
burden of endometrial cancer (Onstad et al., 2016). Cancer mortality is affected 
by incidence, but also the effectiveness of cancer management, which is mainly 
measured by population-based cancer survival. In EUROCARE-5 study (Sant et 
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al., 2015) the survival of gynecological cancers differed widely between count-
ries. The best survival achievements were estimated in the Nordic countries and 
the lowest were shown in Eastern Europe. The comparison of estimates between 
an earlier study EUROCARE-3 (1990–1994) (Sant et al., 2003) and the latest 
EUROCARE-5 (1999–2007) showed significant improvements in gynecolo-
gical cancers’ survival in many European countries, but only modestly im-
proved or unchanged estimates in Eastern Europe, including in Estonia.  
Health care changes, socioeconomic background and societal transition 
during the previous decades have made Eastern Europe, including Estonia, a 
unique region which has been reflected also in dismal gynecological cancer 
trends. 
The estimation of cancer incidence, mortality and survival is important to 
implement cancer control policies and adapt health care services. Knowing the 
epidemiologic cancer trends help to define the priorities for preventive, thera-
peutic and diagnostic strategies in each country and therefore evaluate the out-
comes of interventions, i.e. screening activities in terms of cost and effective-
ness.  
The dismal estimates from previous pan-European studies encouraged more 
specific analysis. 
This thesis contributes to a better understanding of the long-term trends of 
gynecological cancer in Estonia that reflect the socioeconomic changes of 
Estonian society and health care reforms. It is the first comprehensive gyneco-
logical cancer epidemiological study which provides an in-depth analysis of the 
incidence, mortality and survival of corpus uteri, cervical, ovarian and 
vulvovaginal cancer in Estonia. Special emphasis was put on age, morphology 
and stage. The results of the study have important implications for primary and 
secondary cancer prevention, reassessment of current screening policy as well 
as further development of cancer care.  
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2. REVIEW OF LITERATURE 
2.1 Corpus uteri cancer 
2.1.1 Natural history and morphological classification  
of corpus uteri cancer 
Corpus uteri malignancies consist of 90% endometrial carcinomas and 10% 
uterine mesenchymal tumors, sarcomas. Endometrial cancer (carcinomas) arises 
from endometrial tissue which is a hormone responsive tissue. The growth is 
stimulated by estrogen and the cells’ and glands’ maturation is regulated by 
progesterone. In the condition of chronic unopposed estrogen, the endometrial 
cells’ and glands’ growth is not balanced, and abnormal proliferation and neo-
plastic transformation may occur. Atypical adenomatous hyperplasia is the 
premalignant stage of endometrial cancer. Regressed, atrophic endometrium 
could also be the source of intraepithelial cancer which develops into aggressive 
cancer. Endometrial cancer is divided into two main subgroups by histology, 
molecular biology and prognosis (Murali et al., 2017). Type I cancers mostly 
consist of well differentiated, estrogen receptor positive endometrioid adeno-
carcinomas. Type II includes mostly poorly differentiated and estrogen receptor 
negative tumors. The most common histological types are serous carcinomas 
and clear cell carcinomas. 
Uterine sarcomas comprise approximately 5% of uterine corpus malignan-
cies (Prat et al., 2015). These tumors arise from uterine corpus mesenchymal 
tissue. The most frequent histological type is leiomyosarcoma. Other types are 
atypical smooth muscle tumors, endometrial stromal tumors (low-grade endo-
metrial stromal sarcoma, high-grade endometrial stromal sarcoma and undiffe-
rentiated endometrial sarcoma), adenosarcoma. 
Carcinosarcoma (mixed Müllerian tumors) is also classified into type II 
endometrial cancers. These tumors consist of an epithelial component which is 
high grade serous or undifferentiated carcinoma, endometrioid carcinoma and 
high grade sarcoma component (Prat et al., 2015). In this thesis, these tumors 
are included into type II endometrial cancers.  
 
 
2.1.2 Corpus uteri cancer risk factors 
2.1.2.1 Obesity 
The majority (90%) of corpus uteri cancers are endometrial cancers. Obesity is 
the main risk factor for endometrial cancer (Hüsing et al., 2016). It is estimated 
that endometrial cancer relative risk is increased 1.5 times for being overweight, 
2.5 times for class I obesity, 4.5 times for class II obesity and 7.1 times for class 
3 obesity (Lauby-Secretan et al., 2016). Estrogen induces endometrial prolifera-
tion even at an older age. After menopause the estrogen synthesis takes place in 
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adipose tissue. Adipose tissue produces androgens that are converted to estro-
gens with the help of aromatase. Aromatase function and levels are increased 
with age and adiposity. At postmenopausal age, as a result, adipose tissue pro-
duces unopposed estrogen. The mutagenic effect resulting in DNA double-
strand breaks and genetic instability are also described as a result of estrogen 
metabolism (Onstad et al., 2016). 
Increasing obesity has become a world-wide problem (Abarca-Gómez et al., 
2017; Torre et al., 2017). Recent data indicate that approximately 16% of Euro-
pean women are obese (body mass index ≥30) and 31% are overweight (body 
mass index 25–29) (Marques et al., 2018). In Estonia, in 2018, the estimates 
showed that 26% of women aged 16–64 were overweight and 18% were obese 
(Tervise Arengu Instituut, 2018). Being overweight and obese are more 
prevalent in Northern and Eastern Europe than in Southern Europe (Marques et 
al., 2018). For example, obesity is estimated to affect 15–20% of Italian and 
French women, 20–25% of Finnish and Swedish women and 25–30% of 
Latvian, Belarussian and Ukrainian women. 
 
 
2.1.2.2 Other risk factors 
Nulliparity, estrogen-alone hormone replacement therapy (HRT) and diabetes as 
the consequences of being overweight and obese have also shown an unfavor-
able effect on endometrial cancer incidence (Hüsing et al., 2016). The use of 
oral contraceptives has shown a protective role against endometrial cancer 
(Hüsing et al., 2016). 
 
 
2.1.3 Symptoms, pattern of spread and  
treatment of corpus uteri cancer 
For the majority of corpus uteri cancer cases, vaginal bleeding is the first sign of 
the disease. The symptom occurs early in the course of the disease and leads to 
early detection and treatment.  
Endometrial cancers’ spread starts from the endometrium. Then the tumor 
grows through uterine serosa and invades adjacent structures i.e. urinary bladder 
and colon. Endometrial cancer spreads through the pelvic and paraaortic lymph 
nodes. Peritoneal spread and distant metastasis are revealed at a later stage of 
the disease.  
FIGO and TNM classification of stages are used in Estonia and worldwide 
(Brierley et al., 2017).  
The cornerstone of the treatment is surgery. Radical hysterectomy with or 
without pelvic lymphadenectomy is the standard of care. Adjuvant treatment is 
considered at early stages based on the tumor’s clinical and pathological charac-
teristics. Chemotherapy and radiation therapy are shown to benefit overall 
survival if performed as adjuvant treatment. Palliative surgery and palliative 
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chemotherapy are the standard if distant spread is revealed at diagnosis. 20% of 
early stage type I cancers and 50% of early type II cancers relapse (Suarez et al., 
2017). Palliative chemotherapy with platinum compound, taxane and doxorubi-
cin is the treatment of choice in this setting (NCCN, 2019). For Type I cancers, 
hormonal therapies with progestins can be considered. 
 
 
2.1.4 Corpus uteri cancer incidence in the world,  
Europe and Estonia 
The burden of corpus uteri cancer is recognized worldwide. The incidence is in-
creasing in the United States (US), in Europe and in Southern Africa and in 
Asia (Lortet-Tieulent et al., 2018). In the US, the age-adjusted incidence rate is 
estimated to be as high as 27/100 000 women (world) per year (National Cancer 
Institute, 2019). In Europe, the corpus uteri cancer is the fourth most common 
cancer in women with the incidence rate of 20/100 000 women per year (Euro-
pean standard), contributing 6.5% of all female cancer cases in 2018 (Ferlay et 
al., 2018). The highest incidence rates are estimated in Northern and Eastern 
Europe (Lortet-Tieulent et al., 2018). In Bulgaria, Ukraine, Greece, Lithuania, 
Latvia and Slovakia, endometrial cancer has become the third most common 
cancer in women. Corpus uteri cancer was the most common gynecological 
malignancy in Estonia in 2016 (National Institute for Health Development, 
2019). The Estonian age-standardized incidence rate in 2018 was 23/100 000 
women per year (European standard) (J. Ferlay et al., 2018). The comparison of 
incidence rates of corpus uteri cancer in the Nordic and Baltic countries is 
shown in Table 1. 
By histological subtypes, distinct incidence patterns have been observed. 
The United Kingdom (UK) data for the period of 1994–2006 showed that the 
increasing incidence of endometrial cancer was based on the increasing 
incidence of type I cancers while the type II cancers incidence rate did not 
change (Evans et al., 2011). In Denmark, in contrast, the type I incidence had 
been relatively stable during the past ten years, but the overall trend showed a 
decreasing incidence pattern over more than 3 decades (1978–2014). Type II 
cancers trend increased during the same period (Faber et al., 2017). The burden 
of corpus uteri cancer in different countries is based on type I endometrial 
cancers and is concluded as the concurrent effect of the burden of obesity 
(Onstad et al., 2016). 
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2.1.5 Corpus uteri cancer mortality in the world,  
Europe and Estonia 
The mortality rates have shown stable or decreasing rates in the world (Weider-
pass et al., 2014). The estimated mortality rate in Europe in 2018 was 2.9/ 
100 000 women per year (world standard) (Ferlay et al., 2018). In Estonia, an 
increasing mortality trend of corpus uteri cancer was observed in 1980–2008 
(Weiderpass et al., 2014).  
 
 
2.1.6 Corpus uteri cancer survival in Europe and in Estonia 
The European average 5-year relative survival (RS) was 76% in EUROCARE-5 
study (Sant et al., 2015). The significant improvement from 1990–1994 to 
2000–2007 was seen in the 5-year RS estimates in the Nordic countries, 
reaching 86% in Sweden and 83% in Finland in the period of 2000–2007. In the 
Nordic countries the most recent 5-year RS of corpus uteri cancer for the period 
2012–2016 was estimated as 83%–84% (Danckert et al., 2019). According to an 
earlier EUROCARE-3 study (Sant et al., 2003) (1990–1994), Estonian corpus 
uteri cancer survival estimates were one of the lowest in Europe. A later study 
EUROCARE-5 (Sant et al., 2015) (2000–2007) showed some improvement, but 
the Estonian estimates were still within the three lowest in Europe. The 5-year 
RS estimate was 64% in 1990–1994 and improved to 70% in 2000–2007 (Table 
1). The European average survival rates for all age groups had also modestly 
improved (Sant et al., 2015). 
 
 
2.2 Cervical cancer 
2.2.1 Natural history and morphological classification of  
cervical cancer 
Cervical cancer is a malignancy that originates from uterine cervix epithelium. 
Cancer mainly develops from the uterine cervix transformation zone. Trans-
formation zone consists of columnar epithelial cells that transform to squamous 
cells in the ectocervix and to glandular cells in the endocervix. The two major 
histological types of cervical cancer are squamous cell carcinoma and adeno-
carcinoma. Squamous cell carcinomas develop from the ectocervix and adeno-
carcinomas from the endocervix. The cancerous cells are preceded by pre-
cancerous intraepithelial neoplasia (Schiffman et al., 2007).  
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2.2.2 Cervical cancer risk factors 
2.2.2.1 Human Papilloma Virus (HPV) 
HPV is the main risk factor for cervical cancer (Schiffman et al., 2007). About 
99% of all cervical cancers are caused by HPV. The spectrum of Human Papil-
loma viruses is broad, not all of them are found to be related to cervical cancer. 
The most cancerous HPV types for cervical cancer are 16 and 18. HPV 16 is the 
main cause of squamous cell carcinoma and HPV 18 contributes more to adeno-
carcinomas and adenosquamous carcinomas. HPV 16 and HPV 18 are found in 
70% of cervical cancers and 50% of high grade intraepithelial neoplasia. The 
most common HPV types detected in cervical cancer are HPV 16, 18, 33 and 45 
(Schiffman et al., 2007). Cervical cancer related HPV types transmit by skin-to-
skin or by mucosa-to-mucosa contact. Different HPV types may transmit 
together. Cancer develops by certain phases: HPV transmission, HPV persis-
tence, infected cervical cells transform to precancers and invasive cancer. Due 
to the long precancerous phase, the mean age at cervical cancer diagnosis is 35–
55 years. The lifetime probability of acquiring HPV is high, estimated at 91% 
for men and 85% for women (Chesson et al., 2014).The probability of getting 
HPV infection during the first sexual intercourse is about 28% for women 
(Winer et al., 2005). HPV may disappear if once detected at screening. The 
median time for clearance is about 6–18 months. The longer the HPV infection 
persists the stronger the probability of the development of precancerous lesions. 
High risk HPV types (16 and 18) tend to have longer persistence (Schiffman et 
al., 2007). HPV 16 shows clinically detectable premalignant lesions while HPV 
18 does not form as many precancerous lesions that makes the clinical 
prevention difficult. The new infections detected at advanced ages could be the 
previous infections that re-appear or that have been latent before.  
 
 
2.2.2.2 Other risk factors 
The risk of cervical cancer in women who use oral contraceptives for more than 
five years is twice higher than in those who never used them (International 
Collaboration of Epidemiological Studies of Cervical Cancer, 2007). The risk is 
also influenced by the number of sexual partners and more frequent screening. 
Smoking is an independent risk factor for cervical cancer development (Roura 
et al., 2014). The duration and intensity of smoking both increase the risk more 
than twice compared to never smokers. Quitting smoking inversely effects 
cancer development (Roura et al., 2014). Multiparity, having more than 3 
children, is associated with a 2.2 times higher risk of developing precancerous 
high risk cervical intraepithelial neoplasia (CIN 3) (Luhn et al., 2013). The 
association was not consistent with developing invasive cancer. 
Women affected with HIV and with a low CD4+ T-cell count are at a higher 
risk of developing invasive cervical cancer. The low CD4+ T-cell count is 
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associated with a longer persistence of high risk HPV types (Abraham et al., 
2013). 
 
 
2.2.3 Symptoms, pattern of spread and treatment  
of cervical cancer 
Cervical cancer gives no symptoms at the precancerous phase or at an early 
stage. Bleeding after sexual intercourse or vaginal bleedings between menstrual 
periods or at menopausal age are the most common signs at the invasive cancer 
stage. 
Cervical cancer grows locally and invades adjacent structures, urinary 
bladder and rectum. Lymphatic spread appears in pelvic lymph nodes. Distant 
metastases occur frequently in lungs, liver and bones. 
FIGO (2009) and UICC TNM staging systems are currently used to stage 
cervical cancer in Estonia (Brierley et al., 2007). 
The treatment of cervical cancer depends on the tumor stage (McMillian et 
al., 2019). Surgical treatment by conisation, trachelectomy or radical hysterecto-
my are the treatments of choice at the early stages. The surgical approach is 
chosen according to cancer’s clinical and pathological characteristics. Radiation 
therapy with curative intent, both external beam radiation and brachytherapy, 
are applied to locally and regionally spread tumors. The concurrent radio-
sensitizing chemotherapy with platinum compound enhances the radiation treat-
ment effect (Morris et al., 1999) and is established as a standard of care for 
locally advanced tumors. Distant metastatic disease is incurable and is mainly 
treated with palliative chemotherapy. Platinum agent combined with the taxane 
is the preferred regimen and the standard of care today. The newer biological 
agents have shown some effect on metastatic cervical cancer. Bevacizumab 
combined with chemotherapy has favorable outcomes in overall survival 
estimates compared to chemotherapy alone (Tewari et al., 2017). Bevacizumab 
is not reimbursed and not available for cervical cancer patients in Estonia at the 
moment. Immunotherapy has also shown some favorable effect on survival for 
cervical cancer patients (Chung et al., 2019). Pembrolizumab is indicated to 
patients with metastatic or recurrent cancer who have undergone previous 
chemotherapy with platinum compound and progressed. The tumors should be 
evaluated for PD-L1 (programmed death ligand 1) expression. Immunotherapy 
is indicated for cervical cancer patients in the US. 
 
 
2.2.4 Cervical cancer incidence in the world, Europe and Estonia 
Cervical cancer is the most common gynecological cancer in the world, with the 
highest incidence rates in less developed countries, in Latin America and in 
South Africa (Ferlay et al., 2018). The highest incidence rate in 1998–2002 has 
been estimated in Zimbabwe at 87/100 000 women per year and the lowest in 
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Finland at 8/100 000 women per year (world standard) (Vaccarella et al., 2013). 
In the US, the cervical cancer incidence trend is declining (National Cancer 
Institute, 2019). In 1992, the estimated age-standardized incidence rate was 
11.2/100 000 women per year and reached 6.6/100 000 in 2016. In Europe, the 
mean age-standardized incidence rate was estimated at 13/100 000 women per 
year (Ferlay et al., 2018). In the Nordic countries the age-standardized incidence 
rate in 2016 was 8.3/100 000 women per year (Danckert et al., 2019) and the 
incidence trends have been constantly declining during the past decades. In 
contrast, in Eastern Europe (Estonia, Latvia, Lithuania, Russia, Belarus and 
Bulgaria), increasing trends were observed (Vaccarella et al., 2013). In Estonia 
the crude incidence rate was 21/100 000 women per year and the age-
standardized incidence rate was 14.2/100 000 women per year (National Insti-
tute for Health Development, 2019). The comparison of incidence rates by 
countries is shown in Table 1 and demonstrates the gap between Nordic and 
Baltic countries in 2018. The falling incidence trends reflect the well-organized 
nation-wide screening programs (Vaccarella et al., 2014). 
 
 
2.2.5 Cervical cancer mortality in the world, Europe and Estonia 
Cervical cancer mortality rates differ largely in the world. The highest age-
standardized rates above 50/100 000 per women per year were observed in the 
African region and the lowest rates of less than 2.0/100 000 per women per year 
(world standard) in Western and Northern Europe and the Arab countries 
(Ferlay et al., 2018). In most European countries the mortality rate of cervical 
cancer has declined (Arbyn et al., 2009). The lowest mortality rate of 1.1/100 
000 was achieved in Finland in 2000–2004. Mortality rate has increased in 
Latvia, Lithuania, Romania and Bulgaria. The constant high mortality rate was 
observed in Estonia (Arbyn et al., 2009). 
 
 
2.2.6 Cervical cancer survival in Europe and in Estonia 
The survival rates of cervical cancer have risen very modestly during the past 
decades in Europe. The European mean 5-year RS estimate was 62% in 2000–
2007 (Sant et al., 2015) (Table 1). According to EUROCARE-3 study (1990–
1994), the highest 5-year relative survival estimates were observed in Norway 
and Sweden, at 69% in both countries. The lowest estimates were found in 
Poland (48%) and in Estonia (53%). In EUROCARE-5 (2000–2007) the sur-
vival was improved modestly in Norway (71%) and decreased in Sweden 
(67%). The larger improvement was observed in countries with a previous low 
relative survival – Estonia reached 64% and Poland showed 54% of 5-year RS.  
The age-specific 5-year RS did not change between the EUROCARE-3 and 
EUROCARE-5 periods (Sant et al., 2003; Sant et al., 2015). The survival in-
crease was shown for younger women (women aged 15–44 years) from 74% to 
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81% and also for women aged 45–54 years from 66% to 70%. The 5-year RS 
estimate decreased for women aged 65–74 years and was estimated at 51% in 
2000–2007. In the Nordic countries the recent (2012–2016) age-specific 5-year 
RS estimates were 87%–91% for women under 50 years and 51% (Denmark) 
and less for women over 70 years (Danckert et al., 2019). 
 
 
2.2.7 The rationale of cervical cancer screening 
The purpose of cervical cancer screening is to prevent invasive cancer. The 
nation-wide cervical cancer screening programs had been implemented by 2016 
in all European Union member states except Lithuania (Basu et al., 2018). The 
recommendations for the organization and quality assurance for the screening 
activities were composed by the International Agency for Research on Cancer 
under the program “ Europe against cancer” and published in 2010 (Arbyn et al., 
2010). The idea of cervical cancer screening is to detect preinvasive and pre-
cancerous lesions that can be treated successfully and thus the development of 
invasive cancer can be prevented. The conventional screening is based on a Pap 
(Papanicolau) smear test. The test detects cervical cytology changes that could 
develop into cancer or detect already cancerous cells. The HPV-DNA testing is 
also in use in many countries and it could detect persistent moderate and high 
grade cervical intraepithelial neoplasia more often (Basu et al., 2018). The HPV-
DNA testing is considered to be more sensitive than a conventional cytology test 
in detecting cervical adenocarcinoma, but it also may lead to overdiagnosis and 
unnecessary procedures as HPV infection may disappear naturally (Huh et al., 
2015). The age of the target population of screening somewhat varies by 
countries, but most frequently the age group is set between 30–59 years (Anttila 
et al., 2009). The interval between tests is set to be three years in most countries. 
The coverage of the target population is the key feature of a successful 
screening. The decline in incidence is seen in countries with high coverage, 
over 70% of the target population (Anttila et al., 2009; Elfström et al., 2015). 
Low coverage has not shown to result in incidence decline.  
In the Nordic countries, the screening was established already in the be-
ginning of the 1960s and it has shown a rapid and large decline in cervical 
cancer incidence and mortality (Vaccarella, et al., 2014). The cervical cancer 
incidence declines were also observed in the US, Canada and Australia after the 
implementation of screening programs (Dickinson et al., 2012; Vaccarella et al., 
2013). Regular monitoring of the quality indicators in organized screening is a 
prerequisite for successful outcomes. 
Regular participation in screening is estimated to prevent up to 83% of 
deaths due to cervical cancer (Landy et al., 2016). 
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2.2.8 HPV vaccination 
The aim of HPV vaccination is to avoid the cell changes influenced by different 
HPV types that could lead to the development of precancerous lesions or cancer. 
The vaccine produces antibodies against HPV that could be detected within 10 
years after the vaccination. Later, the prevention and the detection of HPV 
related cell damages could be examined by screening, cytological (Pap-smear 
test) or molecular HPV detection. Vaccination is most efficient during adole-
scence and for persons who had not become sexually active yet. The immuno-
genic boost after the vaccination is tested to be weak if a woman has already 
been infected with HPV and the cross-immunity had not been detected (Harper 
et al., 2017; Schiffman et al., 2007). 
From 2007 the vaccination of girls was implemented into the national vac-
cination plan in Germany, France and Belgium (Bonanni et al., 2011) and more 
countries followed the action within the next few years. The vaccination for 
adolescents consists of two injections in a six month or a year interval. The 
vaccination schedule is recommended by the World Health Organisation 
(WHO, 2019). 
 
 
2.3 Ovarian Cancer 
2.3.1 Natural history and morphological  
classification of ovarian cancer 
Ovarian cancer is a heterogeneous group of malignancies which arises from 
ovarian tissue or fallopian tubes’ secretory epithelial cells or progenitor cells 
(Karnezis et al., 2017). Ovarian cancer is divided into two main subgroups 
based on histological type. Epithelial ovarian cancers comprise approximately 
85–90% of all ovarian malignancies. They consist mainly of high grade serous 
carcinomas (70%), low grade serous carcinomas, endometrioid carcinomas, 
mucinous carcinomas and clear cell carcinomas. Non-epithelial ovarian malig-
nancies cover 10–15% of cases. The main histological subtypes are germ-cell 
tumors and sex-cord tumors. 
 
 
2.3.2 Ovarian cancer risk factors 
There are certain established adverse risk factors and protective factors for ova-
rian cancer development. Based on distinct molecular and histological charac-
teristics, ovarian cancer risk factors also vary by subtypes (Webb et al., 2017). 
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2.3.2.1 Ovarian cancer adverse risk factors 
2.3.2.1.1 Genetic predisposition of ovarian cancer 
It is well described that an individual woman’s family history of ovarian cancer 
and breast cancer raises the likelihood of developing ovarian cancer. 14% of all 
epithelial ovarian cancers are found to have pathogenic mutations in BRCA 1 or 
BRCA 2 genes (Alsop et al., 2012). BRCA genes produce tumor suppressor 
proteins and are responsible for DNA repair (Venkitaraman, 2002). The most 
common genetic syndrome caused by pathogenic BRCA mutation is the here-
ditary breast and ovarian cancer. Women with BRCA 1 mutation have a life-
time risk to develop ovarian cancer of about 40% up to 70 years of age, and the 
risk is 16% for BRCA 2 mutation (King et al., 2003). Both breast and ovarian 
cancers represent 5% among BRCA 1 and 2% among BRCA 2 carriers (Reb-
beck et al., 2015). BRCA-related ovarian cancer patients tend to be younger 
than sporadic ovarian cancer patients (Cass et al., 2003). The cancer is charac-
terized by high grade histology and the tumors are very sensitive to platinum-
based therapy (Cass et al., 2003). The overall survival of BRCA-related cancers 
is more favorable than for sporadic cancers (Bolton et al., 2012). BRCA muta-
tion testing is recommended by international clinical guidelines for ovarian 
cancer patients (NCCN, 2019). The aim of BRCA testing is to guide the treat-
ment choices (Mirza et al., 2018) and perform genetic counselling for family 
members for the prevention of BRCA-related cancers. BRCA testing has be-
come a standard of care for epithelial ovarian cancer patients in Estonia. 
2.3.2.1.2 Endometriosis 
Endometriosis as a benign disease is found to be associated with certain types of 
epithelial ovarian cancers (Pearce et al., 2012). Clear cell, low-grade serous and 
endometrioid carcinomas are suggested to be associated with endometriosis 
while high grade serous and mucinous carcinomas are not. The exact underlying 
mechanism is not well clarified. ARID1A as a tumor suppressor gene is found 
to be mutated in 46% of clear cell ovarian cancers and 30% of endometrioid 
ovarian cancers (Wiegand et al., 2010). 
2.3.2.1.3 Menopausal hormone therapy 
Menopausal HRT is found to increase the risk of high grade serous and endo-
metrioid ovarian cancer (Collaborative Group on Epidemiological Studies of 
Ovarian Cancer, 2015 ). A meta-analysis estimated the increased risk for all 
HRT users compared to never users. The risk increased with the duration of 
HRT and decreased after the cessation of therapy. The risk remained elevated 
even 10 years after the therapy for serous and endometrioid ovarian cancer. The 
conclusion was that one extra ovarian cancer case would be diagnosed per 1000 
menopausal HRT users. 
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2.3.2.2 Ovarian cancer protective risk factors 
2.3.2.2.1 Oral contraceptives 
Oral contraceptives are established as protective factors of ovarian cancer. The 
combined mechanism of estrogen and progestin causes anovulation. It was 
estimated that by 2008, oral contraceptives had prevented 200 000 new ovarian 
cancer cases and 100 000 deaths (Collaborative Group on Epidemiological 
Studies of Ovarian Cancer, 2008). The strongest effect is achieved in reducing 
ovarian cancer by using oral contraceptives among women under 30 years with 
a duration of 10 years and over (Havrilesky et al., 2013). Oral contraceptives 
were introduced to the world in 1960 in the US. More frequent use started in 
Estonia in the late 1990s. In 2018, oral contraceptives were the 15th most fre-
quently prescribed medicine in Estonia (Sammul et al., 2018). 
2.3.2.2.2 Breast feeding 
Breast feeding is found to reduce ovarian cancer risk. The duration of breast 
feeding for more than 3 months is associated with a 27% reduced risk of 
ovarian cancer and it is estimated to last up to 30 years. The greater the duration 
of breastfeeding and the number of offspring, the more the risk is reduced 
compared to women who never breastfed (Modugno et al., 2019).  
2.3.2.2.3 Pregnancy 
Parous women are found to have a reduced ovarian cancer risk compared to 
nulliparous women (Koushik et al., 2017). The risk decreases with an increasing 
number of pregnancies. A woman with two pregnancies has a 50% lower risk of 
ovarian cancer than a woman without pregnancies. 
 
 
2.3.2.3 Other factors 
Mucinous ovarian cancer risk is found to be increased among tobacco users 
(Webb et al, 2017) but no other histological types. Obesity is found to be an 
adverse risk factor for endometrioid ovarian cancer but not for high grade 
serous cancers. Physical activity and alcohol consumption have not shown a 
relation to ovarian cancer risk (Webb et al., 2017). 
 
 
2.3.3 Symptoms, pattern of spread and  
treatment of ovarian cancer 
At early stages, ovarian cancer gives no specific symptoms. Tumors at early 
stages are found mostly incidentally by ultrasonography (Smith-Bindman et al., 
2019). At later stages, abdominal mass, abdominal distention or increased girth, 
abdominal or pelvic pain, abdominal or pelvic bloating, and loss of appetite 
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may occur (Ebell et al., 2016). Symptoms are not specific for ovarian cancer 
and might lead to discover other health problems. 
The high lethality of ovarian cancer is caused by its pattern of spread. The 
spread to peritoneal surfaces occurs early in the course of the disease and this 
makes ovarian cancer incurable. Regional spread to lymph nodes includes 
inguinal, pelvic and paraaortic nodes. Hematogenic spread is revealed mostly in 
the liver, pleura, lungs and non-regional lymph nodes. 
FIGO and TNM staging systems are used to describe ovarian cancer stages 
(Brierley et al., 2017).  
Treatment of ovarian cancer has evolved over the past decades and needs a 
multidisciplinary approach today. Surgery with the aim of cure at early stages 
(IA) and cytoreduction at later stages is the cornerstone of the treatment 
(NCCN, 2019). The standard approach is to remove both ovaries with adnexa, 
uterus and omentum. The goal of the surgery at later stages is to achieve opti-
mal cytoreduction with no visible residual tumor in the peritoneal cavity (Du 
Bois et al., 2009.). Optimal cytoreduction for advanced stages (IIB-IV) is found 
to be the most powerful prognostic factor for survival. Hyperthermic intra-
peritoneal chemotherapy (HIPEC) has shown favorable outcomes in patients 
who underwent optimal cytoreduction (Van Driel et al., 2018), but the data are 
considered immature to perform HIPEC as standard of care. Chemotherapy is 
the standard approach for adjuvant treatment. Platinum-based combinations 
have been used for many decades. Chemotherapy might be used as neoadjuvant 
therapy when optimal cytoreduction as frontline therapy is impossible due to 
high tumor volume (Wright et al., 2016). The latest advances in ovarian cancer 
treatment apply mostly for epithelial ovarian cancer. Maintenance therapy for 
advanced stages has become a standard (Randall et al., 2019). PARP- inhibitors 
have shown significant improvement in progression free survival for high grade 
epithelial ovarian cancer both after frontline and after platinum-sensitive 
relapse. Bevacizumab maintenance therapy after frontline therapy and after 
platinum sensitive relapse has also shown favorable outcomes. At phases when 
epithelial ovarian cancer is considered platinum resistant, chemotherapy with 
other agents is the treatment of choice (Ledermann et al., 2013; NCCN, 2019). 
 
 
2.3.4 Ovarian cancer incidence in the world, Europe and Estonia 
Ovarian cancer incidence trends vary worldwide (Coburn et al., 2017) with the 
mean age-standardized incidence rate of 6.6/100 000 women per year (Ferlay et 
al., 2018b). The highest incidence rates are found in Eastern and Northern 
Europe (Ferlay et al., 2018) (Table 1). In the US, the age-adjusted incidence rate 
was 11/100 000 women per year (National Cancer Institute, 2019) in 2016 and 
in Europe the crude rate was 18/100 000 women per year, and the age-
standardized incidence rate was 10/100 000 women per year. In Eastern Europe, 
the age-standardized incidence rate is the highest in Poland (14.7/100 000) and 
in Belarus (15.4/100 000) (Ferlay et al., 2018). 
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In the US, the incidence decline by APC 1.1% has been observed during 
1988–2008 (Lowe et al., 2013). The decline was eminent both in women less 
than 65 years and over 65 years of age. In the Nordic countries the decline has 
been significant among women under 70 years during 1993–2013 (Gottschau et 
al., 2016) while the stable trend is observed among women over 70 years, 
except in Sweden, where the decline has been continuous during the studied 
period. In Estonia the incidence trend has been stable over the decades (Coburn 
et al., 2017). 
The decline of the incidence is found to be related to more frequent oral 
contraceptive use and less frequent menopausal hormone therapy (Sopik et al., 
2015). The countries where the incidence trends are increasing, the estimates 
are associated with decreased parity (Coburn et al., 2017). 
 
 
2.3.5 Ovarian cancer mortality in the world,  
Europe and Estonia 
Ovarian cancer is considered to be the most aggressive cancer of the female 
genital organs. The mean age-standardized mortality rate in the world was 
3.9/100 000 women per year (world standard) in 2018 (Ferlay et al., 2018) with 
the highest estimates in Eastern Europe (7.8/100 000 in Poland, Latvia and 
Lithuania) and the lowest estimates under 1.0/100 000 women per year in 
Belize and in the Republic of Gambia. The European mean age-standardized 
mortality rate was 5.1/100 000 women per year which was lower than the 
estimate in Estonia (Table 1). 
The trends in ovarian cancer mortality have been stable or declining in most 
parts of the world (Malvezzi et al., 2016). In countries of South America and 
South Korea increasing trends were observed. The only country in Europe with 
the increase in mortality (28%) was Bulgaria.  
Mortality trend in Estonia from 2002 to 2012 showed the largest mortality 
decline in Europe (Malvezzi et al., 2016). The improvement was seen in every 
age group. 
 
 
2.3.6 Ovarian cancer survival in Europe and in Estonia 
The European average 5-year RS increased modestly from 1990–1994 to 2000 – 
2007, from 37% to 38%, respectively (Sant et al., 2003; Sant et al., 2015). In 
Northern Europe the 5-year RS estimates were observed at 40% and over 
already in 1990–1994; in Sweden (41%) and Norway (40%). In EUROCARE-5, 
the average 5-year RS was 41% in the Nordic countries with the highest rate of 
44% in Sweden (Table 1). The most recent estimates showed larger improve-
ment in Denmark where the 5-year RS for the period 2012–2016 reached 41% 
and modest improvements in Norway (45%) and Sweden (49%) (Danckert et 
al., 2019). There has been no improvement in Finland (44%) during the past 10 
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years. The Estonian 5-year RS estimates improved from 26% in 1990–1994 to 
34% in 2000–2007 (Sant et al., 2003; Sant et al., 2015). 
The 5-year RS have improved very modestly during the past 25 years in 
countries with high quality cancer care. The rates have not exceeded 50% yet in 
Sweden or in Norway.  
Despite of the improvements in short-term and 5-year RS, there were no 
improvements in 10-year survival observed in the Netherlands. 10-year RS 
estimate of 24% for ovarian cancer has not changed since the early 1990s 
(Timmermans et al., 2018).  
 
 
2.3.7 Hereditary ovarian cancer prevention 
There is no effective screening strategy for ovarian cancer. The detection of 
women with suspicious hereditary cancer syndromes is the only possibility to 
reduce the incidence of ovarian cancer within the high-risk family members. 
Hereditary cancer syndromes are detected and counselled by a clinical gene-
ticist. International guidelines recommend BRCA testing for all epithelial 
ovarian cancer patients except mucinous cancers (NCCN, 2019). The Australian 
study found 14% of epithelial ovarian cancer were related BRCA gene muta-
tions and 30% of these women did not have a family background of hereditary 
breast and ovarian cancer syndrome (Alsop et al., 2012). Prevention of ovarian 
cancer or other cancers of the hereditary syndrome could be considered if one 
family member is already found to have a hereditary high-risk cancer gene 
mutation. The same mutation could be detected in other blood related relatives. 
The prevalence of BRCA pathogenic mutations are about 1.0% to 2.5% of 
entire female population (Metcalfe et al., 2009). The idea of testing high risk 
cancer genes in all populations has already been put under discussion.  
The international guidelines recommend to undergo preventive procedures 
before the age 40 (NCCN, 2019; Paluch-Shimon et al., 2016). Ovarian cancer 
prevention consists of the removal of the fallopian tubes and ovaries. As there is 
more etiological information that high grade serous ovarian cancer begins from 
the fallopian tubes (Kurman, 2013), the discussion about the removal of tubes 
only is underway (Gockley et al., 2018). Oral contraceptives are effective in 
preventing ovarian cancer and also among BRCA gene mutation carriers. Oral 
contraceptives are recommended as a preventive strategy for hereditary ovarian 
cancer (Paluch-Shimon et al., 2016). 
None of the preventive measures can entirely avoid the development of 
ovarian cancer. Therefore the more frequent scheduled gynecologist visits with 
a transvaginal ultrasound and evaluation of cancer antigen CA 125 are re-
commended by guidelines and should be performed from the age of 35 years 
(NCCN, 2019; Paluch-Shimon et al., 2016). 
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 2.4 Vulvar and vaginal cancer 
2.4.1 Natural history and morphological classification of  
vulvar and vaginal cancers 
The vulva consists of female outer genital organs: labia majora and minora, 
clitoris, vestibule, vaginal introitus and urethral meatus. About 95% of vulvar 
malignancies are squamous cell carcinomas.  
The vagina is a female internal genital organ and lies in the pelvis and is 
surrounded in distal with the vulva and in proximal with the uterine cervix, 
while in the interior lies the urinary bladder and the rectum is located in the 
posterior. The majority of vaginal cancers are squamous cell cancers, appro-
ximately 10% are adenocarcinomas and a small entity consists of clear cell 
carcinomas. Vaginal adenocarcinomas and clear cell carcinomas are extremely 
rare cancers and are revealed in young women and adolescents. 
 
 
2.4.2 Vulvar and vaginal cancer risk factors 
2.4.2.1 Vulvar cancer risk factors 
2.4.2.1.1 Lichen sclerosus 
Lichen sclerosus is a chronic inflammatory skin disorder that usually affects the 
vulva and groin. It is found that with the ageing population, the incidence of 
lichen sclerosus has doubled during the past two decades (Bleeker et al., 2016). 
The average age of lichen sclerosus diagnosis is 60 years. Lichen sclerosus is 
the underlying condition for the development of differentiated vulvar intra-
epithelial neoplasia (dVIN). The cumulative incidence of vulvar cancer with 
lichen sclerosus is 7% in 10 years and it increases with age (Bleeker et al., 
2016). Lichen sclerosus is not associated with HPV. 
2.4.2.1.2 HPV 
HPV is associated with high risk VIN (Alkatout et al., 2015). The main HPV 
type that has been found in high risk VIN is HPV type 16 (82%). The trans-
mission of HPV is similar to what was previously described in the cervical 
cancer risk factors section. HPV induced VIN is found more in younger women 
(92% in women aged 50–59 versus 0% in women aged 80 years and over) 
(Wakeham et al., 2017). HPV-related vulvar carcinoma has shown better treat-
ment outcomes. The 5-year survival is estimated 78% in HPV positive versus 
49% in HPV negative women (Wakeham et al., 2017).  
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2.4.2.2 Vaginal cancer risk factors 
The main risk factors for vaginal cancer are HPV types 16 and 18 (Daling et al., 
2002). The premalignant lesions as vaginal intraepithelial neoplasia (VAIN) are 
associated with HPV. HPV transmission is similar as described in the cervical 
cancer and vulvar cancer section. 30% of vaginal cancer patients have suffered 
previously from another anogenital cancer. The other established risk factors are 
current smoking, early age (under 17 years) of first intercourse and more than 
five sexual partners. 
 
 
2.4.3 Symptoms, pattern of spread and treatment of 
vulvovaginal cancer 
The symptoms of vulvar cancer are pruritus, vulvar lump, vulvar bleeding, 
dysuria, discharge and pain (Alkatout et al., 2015). 
The symptoms of vaginal cancer are commonly painless vaginal bleeding 
and discharge. In more advanced tumors the extension to adjacent organs and 
structures may mimic the symptoms of colorectal or bladder cancer (Di Donato 
et al., 2012). 
Vulvar cancer grows first locally by invading adjacent structures (urethra, 
anus, vagina). The following regional lymphatic spread includes inguinal, 
femoral and pelvic lymph nodes. Distant metastasis is revealed most commonly 
in the liver, lungs and bones. 
Vaginal cancer grows locally and spreads further onto adjacent organs and 
into the pelvic wall. Metastases in distant organs appear in the late course of the 
disease. 
Vulvar and vaginal cancers are staged by FIGO and TNM staging systems 
(Brierley et al., 2017). 
Three-quarters of patients suffering from vulvar or vaginal cancer are over 
60 years old. The treatment of vulvar and vaginal cancers causes major effects 
on quality of life.  
Surgery is the standard of care of locally and regionally spread vulvar 
tumors. Patients who are not candidates for surgery, radiotherapy or chemo-
radiation is the preferred treatment modality. In case of distant metastatic 
disease, palliative chemotherapy with platinum compound is the standard of 
care (NCCN, 2018). Local small vaginal invasive cancers are treated with 
surgery alone. External beam radiotherapy and brachytherapy are the treatment 
of choice at a more advanced disease (Di Donato et al., 2012). 
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2.4.4 Vulvovaginal cancer incidence in the world,  
Europe and Estonia 
Vulvovaginal cancers contribute 5% of all gynecological cancers in the world 
(Ferlay et al., 2018) and 7% in Europe. Vulvar cancer overall age-standardized 
incidence rate is observed at 0.88/ 100 000 per year (world standard) (Ferlay et 
al., 2018) in 2018 in the world and 1.7/100 000 in Europe. Vaginal cancer age-
standardized incidence rates were 0.37/100 000 and 0.32/100 000, respectively. 
The increasing incidence trend of vulvar and vaginal cancers have been 
observed over the past decades in different countries (Barlow et al., 2017). The 
increasing prevalence of HPV is considered to be the main cause of vulvar 
cancer incidence increase among younger women (Hampl et al., 2008; Kang et 
al., 2017). In Australia, over the period 1982–2009 the overall incidence rate 
did not change (Barlow et al., 2015) but the significant increase of 82% was 
observed among younger women. In the UK, the significant increase of overall 
incidence was shown (Lai et al., n.d.) during the period 1990–2009. The 
increase was most prominent for the age group of 70 years and younger. The 
incidence decreased significantly for women age 80 and over. Despite the majo-
rity of vulvar cancer cases occurring in women 70 and older, the shift toward 
earlier stages at diagnosis has been observed in Germany and Australia.  
 
 
2.4.5 Vulvovaginal cancer mortality in the world and Europe 
The mortality of vulvar cancer is generally low, estimated age-standardized 
mortality rate of 0.27/100 000 per year in the world and 0.51/100 000 per year 
in Europe. Vaginal cancer showed the age-standardized mortality rate of 
0.16/100 000 per year in the world and 0.12/100 000 per year in Europe (Ferlay 
et al., 2018a). Vulvar cancer mortality has significantly decreased for women 
aged 60 years and over during the past decades. Still, the mortality rates are 
higher at older age groups and estimated at 12/100 000 women per year (Barlow 
et al., 2015) and less than 0.5/100 000 women per year among women under 60 
years. 
 
2.4.6 Vulvovaginal cancer survival in Europe 
According to EUROCARE-3 and 5 studies the survival of vulvovaginal cancer 
has improved. The European mean 5-year RS improved from 52% to 57% 
during the period 1990–2007. The dismal estimate of 34% of 5-year RS in 
Estonia in 1990–1994 had improved up to 53% in 2000–2007 (Sant et al., 2003; 
Sant et al., 2015). The relative survival in Europe improved for all age groups 
according to pan-European studies (Sant et al., 2015). The survival by stages 
have shown different long-term patterns. The 5-year RS for localized disease is 
about 80% and for distant metastatic disease the rate stays as low as 20% 
(Tanaka et al., 2019).  
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2.5 Cancer care, prevention and registration in Estonia  
2.5.1 Health care organization for cancer care in Estonia 
In Estonia, the Ministry for Social Affairs is responsible for the planning of 
health policy and its implementation, and ensuring the availability of health 
services, quality and safety (Ministry of Social Affairs, 2019). Primary care is 
organized based on family doctors who work as self-employed all-around Esto-
nia. Specialist care is organized in the hospitals or in private offices. The 
services provided by different type of hospitals are laid down by the regulations 
of the Minister for Social Affairs in 2004 “Requirements for Hospitals’ Types” 
(Sotsiaalminister, 2004). 
Gynecological services are provided in every type of hospital and in private 
offices. No referral from a family doctor or other specialist is needed (Eesti 
Haigekassa, 2019). 
Estonia has a solidary health insurance system that covers health care costs 
independently of patient’s income, age or health care risks (Eesti Haigekassa, 
2019). In addition to employed persons, the insurance covers treatment costs for 
children, seniors, mothers who are raising small children at home, the un-
employed and pregnant women. 
The major hospital reform took place during 1998–2001. According to the 
regulations by the minister for social affairs in 2004, cancer care can be per-
formed only in regional and central hospitals. Currently, there are five hospitals 
which perform cancer treatment.  
Estonia has no current National Cancer Plan. Previous plan ended in 2015 
(Paat-Ahi et al., 2017). The plan was composed in 2006 and set the goals for the 
prevention and early detection of cancer, cancer care and rehabilitation, pallia-
tive care and hospice. The increasing cancer incidence and the lack of availabi-
lity of cancer care were highlighted as the current situation in the strategy. The 
indicators to evaluate the progress were described. The overall cancer incidence 
and mortality were expected to decline by 5% and 10% accordingly during the 
strategy period. The indicator for cervical cancer incidence and mortality were 
defined and 20% of incidence and 30% of mortality reduction were expected. 
The indicator for cervical cancer screening was set to cover 70% of all the target 
population. The 5-year relative survival estimates were expected to improve for 
cervical cancer from 53% to 65% and for corpus uteri cancer from 64% to 75%. 
The evaluation analysis of the National Cancer Plan in 2017 pointed out the 
dismal results (Paat-Ahi et al., 2017). The cancer incidence rose 25% and the 
mortality rose 9% for men and 17% for women during 2003–2014. Cervical 
cancer incidence and mortality continued to rise and the coverage by screening 
did not reach 50% of the target population. The goals were achieved in survival 
indicators – most cancers’ survival increased. 
The regulation for delivering and measuring cancer care services was 
adopted by the minister for social affairs in 2011 (Minister of Social Affairs, 
2011). The aim of the regulation was to help to achieve the goals proposed in 
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the National Cancer Plan. The quality indicators set in the document are on-
going and compulsory to measure, monitor and report yearly by each hospital 
delivering cancer care. 
 
 
2.5.2 Quality assurance 
The quality of health services is monitored by the Estonian Health Insurance 
Fund (EHIF). EHIF is a governmental body founded in 2000 to organize the 
national health insurance, offer the health insurance and to ensure the health 
care, prevention and compensation for people with health insurance in Estonia. 
The quality is monitored by controlling the health care institutions with the 
EHIF contracts of compensation of health services, conducting clinical audits 
and measuring clinical indicators.  
The EHIF audits of treatment quality of cervical cancer and ovarian cancer 
were conducted in 2016 (Eesti Haigekassa, 2019). All four hospitals which pro-
vide gynecological cancer care were studied. 80 cases for ovarian and 80 cases 
for cervical cancer were evaluated for waiting-times, diagnostics, performance 
of multidisciplinary meetings, surgery, radiotherapy for cervical cancer, chemo-
therapy and documentation of follow-ups. Additionally, the expert opinion 
about the adherence to international guidelines was given. The main findings 
were incomplete documentation for waiting-times, only 75% of ovarian cancer 
cases were discussed in multidisciplinary meetings before any oncological 
treatment and prolonged waiting times (more than 42 days) for curative radio-
therapy in cervical cancer cases were observed (Eesti Haigekassa, 2019). 
In 2017 and 2018 the Treatment Quality Board and the Guideline Advisory 
Board was established and supported by EHIF (Eesti Haigekassa, 2019). The 
aim of the boards is to promote the collaboration of hospitals and specialists in 
developing and implementing quality care. The Treatment Quality Board 
focuses on the development of clinical quality indicators for monitoring the 
treatment quality. In 2018, 6 treatment quality indicators were adopted for the 
diagnostics and treatment of cervical cancer. The Treatment Guidelines Board 
produces treatment guidelines and patient management pathways. The manage-
ment pathways of cancers are the suggested patient management algorithms 
from the suspicion of cancer by a primary care doctor or screening until death 
due to cancer. In 2016, patient management pathways for vulvar, cervical, 
corpus uteri cancer and ovarian cancer were adopted and published. 
 
 
2.5.3 Diagnostics and treatment 
The diagnostics with magnetic resonance tomography and computed tomo-
graphy (CT) have been available for patients for more than 15 years. Ultrasound 
diagnostics for gynecological diseases were largely used from the end of the 
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1980s. Positron emission tomography for cancer diagnostics is available since 
2002.  
The implementation of new surgical modalities has been taken into practice. 
For example, in 2016, 57% of hysterectomies were performed by laparoscopic 
surgeries compared to 35% in 2011 (Veerus et al., 2015). The robotic surgery 
has not reached Estonia yet.  
Globally, the advances in systemic treatment for gynecological cancers have 
recently made a major impact on prolonging patients’ lives and improving 
quality of life. In Estonia, new systemic treatments are implemented into every-
day practice with a delay compared to other European countries (Cherny et al., 
2016). The procedure for drafting and amendment of a list of medicinal pro-
ducts of EHIF is regulated by the regulation of the Minister of Health and 
Labour which was implemented in 2018 (Minister of Health and Labour, 2018). 
Radiation therapy for gynecological cancers has been performed in two 
hospitals – in the Tartu University Hospital and in the North Estonia Medical 
Center. Brachytherapy for cervical cancer was performed only in the North 
Estonia Medical Center until 2018. The first linear accelerator was received in 
the Tartu University Hospital in 1996. Today, there are six linear accelerators 
working in Estonia, four machines in the North Estonia Medical Center and two 
in the Tartu University Hospital. The availability of radiotherapy has been 
estimated as not optimal (Borras et al., 2015) and it should be improved in 
Estonia. 
 
 
2.5.4 Estonian Cancer Registry (ECR) 
ECR is a population-based registry and covers the whole Estonian population. 
The Registry was founded in 1978 and it collects the data about all incident 
invasive cancer cases diagnosed in Estonia since 1968. From 1994 all in situ 
cases and from 1998, brain and central nervous systems tumors and tumors of 
uncertainty for malignant potential or benign origin of endocrine organs 
locating in the brain area are collected. The data collection is regulated by law, 
and the current ECR legislation is in force from the 15th of March 2019. The 
aims of the registry are to analyze cancer incidence, prevalence and survival; to 
organize health care services and cancer control; to develop health policies; to 
evaluate cancer diagnostics and treatment and to facilitate cancer research. The 
reporting of cancer cases (diagnosis and treatment) is compulsory for all clini-
cians, pathologists and forensic doctors. There are reporting forms for physi-
cians and pathologists who diagnose and treat cancer (Appendix 1 and 2). The 
form for clinicians consists of patient’s personal data (name, personal identity 
code, gender, time of birth, the residence at the time of diagnosis), diagnosis 
(date of first diagnosis, the investigational methods that confirmed the diag-
nosis, morphologic diagnosis, tumor grade, extent of disease and TNM stage), 
frontline treatment by specialty (the intention of treatment, place of the treat-
ment, date of the beginning of treatment, treatment method), the date of death 
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and the cause of death or the date of emigration and the data about the person 
who filled in the form (National Institute for Health Development, 2019). The 
data is tracked from multiple sources including the Estonian Population 
Register, Estonian Causes of Death Registry and through linkage with the data-
bases of two regional hospitals. ECR uses the International Classification of Di-
seases for Oncology, currently the third edition (ICD-O-3) (Fritz et al., 2000), 
for tumor classification.  
 
 
2.5.5 Cervical cancer screening in Estonia 
From 2003, in Tallinn and in Tartu the first projects of cervical cancer screening 
activities were established. A nation-wide screening started in Estonia in 2006. 
Women aged 30, 35, 40, 45, 50 and 55 with valid health insurance are notified 
every five years by a letter to participate in a screening program and give a Pap-
smear test. Women diagnosed with cervical cancer within the previous 60 
months are not invited. The screening is voluntary and there are no restrictions 
if screening is skipped. The Pap test can be performed in the health care insti-
tutions holding a screening contract with the Estonian Health Insurance Fund 
(over 20 institutions in Estonia). The guidelines for taking the Pap test is 
adopted by the Estonian Gynaecologists’ Society (Aavik et al., 2011). Estonian 
Cancer Screening Register is responsible for sending out the notification letters. 
The Register was established in 2015 with the aim to coordinate and analyze 
cancer screening data, evaluate the screening activities and offer the platform 
for future research. The cervical cancer screening in Estonia has been estimated 
as ineffective despite of more than 10 years of screening. Cervical cancer 
incidence has not decreased in Estonia (Vaccarella et al., 2016). The involve-
ment of the target population has been low from the beginning of screening 
activities, only 20–40% (Kivistik et al., 2011). A study examined the reasons 
for the low participation rate and concluded that Estonian women did not have 
enough information about the program (Kivistik et al., 2011). One of the 
reasons not to attend the screening program was the recent Pap-smear test per-
formed outside the program. The differences in socioeconomic background of 
women may affect the participation in cervical cancer screening. Higher level of 
education, younger screening age group and Estonian citizenship were shown to 
be positively associated with screening participation (Koreinik, 2019). In 2017, 
the overall participation rate published by the Estonian Cancer Screening Regis-
ter was 31% (National Institute for Health Development, 2019). The rate of the 
screened target population differed by counties. The highest participation rate 
was shown in Järva county at 53% and the lowest was in Pärnu county and esti-
mated at only 3%. The data gathered by the Register was compared to the 
Estonian Health Insurance Fund’s data on performed Pap tests and the coverage 
of 67% of the target population was estimated overall. 
From 2018 the HPV vaccination with the nonavalent vaccine was included 
into the Estonian national vaccination program for girls aged 12–14. In 2020, 
33 
only girls aged 12 will be included. The vaccination takes place at schools and 
is performed by a health care professional. The vaccination can be performed by 
a family doctor also. The vaccination is voluntary and for free. A consent from 
a parent is needed to perform the vaccination. 
 
 
2.6 Summary of the literature review 
Gynecological cancers contribute a large proportion of all cancers in women 
and affect deeply women’s reproductive function, quality of life and cause 
premature death. 
Globally, the trends of gynecological cancers are influenced by a number of 
individual, societal and health care factors. Incidence trends are affected by 
demographic changes, but also by changes in the prevalence of risk factors, 
such as obesity for corpus uteri cancer, oral contraceptive use for ovarian 
cancer, and sexual behavior for cervical cancer and vulvovaginal cancer, and by 
health care interventions, such as screening and HPV vaccination for cervical 
cancer. Survival trends show marked variations across Europe and are heavily 
dependent on the availability and quality of cancer care in a particular country. 
Previous international and other studies of gynecological cancer trends have 
shown dismal results for Estonia. These patterns are not well understood. The 
transition from Soviet to Western society has made an impact on women’s 
health behavior and brought along altered risk factor profiles. The changes in 
dietary preferences and physical activity, sexual behavior and birth control 
methods reached Estonia later than Western Europe. At the same time, major 
efforts have been undertaken to improve health care organization, the availabi-
lity of modern diagnostic and treatment options, and the quality of cancer care. 
Nation-wide cervical cancer screening program has been in place in Estonia for 
over ten years. An in-depth analysis of long-term trends has not been carried out 
before and the need to examine whether the above-mentioned changes and 
cancer control activities have influenced recent outcomes of gynecological 
cancers in Estonia has been recognized. The results of the study are expected to 
provide input for health policy decisions in the future. 
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3. AIMS OF THE RESEARCH 
The general aim of the research was to obtain a better understanding of the 
long-term epidemiological trends in the incidence, mortality and survival of 
gynecological cancers in Estonia, in the context of societal and healthcare tran-
sition, changing risk factor profiles and cancer screening activities.  
The specific aims were: 
1 To evaluate corpus uteri cancer incidence, mortality and survival trends 
in Estonia by age, stage and histological subtypes, with an emphasis on 
surgical treatment. 
2 To examine cervical cancer incidence, mortality and survival by age, 
stage and histology in Estonia, with a particular focus on birth-cohort 
and period effects. 
3 To analyze the incidence, mortality and survival trends of ovarian 
cancer by age and stage in Estonia. 
4 To describe the incidence, mortality and survival of vulvar and vaginal 
cancers in Estonia. 
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4. MATERIALS AND METHODS 
4.1 Data sources 
The data on incident cases were obtained from the ECR, a population-based 
register collecting data on all newly diagnosed cancer cases in Estonia (see 
2.5.4). 
The data on deaths were provided by the Estonian Causes of Death Registry. 
The registry collects information on death certificates which are filled in by 
doctors or forensic doctors who ascertain the person’s death. The registry was 
established and started to collect data on the 1st of January 2008. Before the 
date, the data about causes of death were collected by Statistics Estonia 
(National Institute for Health Development, 2019). Mortality data are available 
from 1984; causes of death have been classified according to International 
Classification of Diseases (ICD) starting from 1995. 
Population denominator data were obtained from Statistics Estonia (Statis-
tics Estonia, 2019). 
Estonian Population Register that was used for vital status follow-up is a 
database which unites the main personal data on Estonian citizens and citizens 
of the European Union who have registered their residence in Estonia and aliens 
who have been granted a residence permit or right of residence in Estonia 
(Population Register, 2019).  
 
Data definitions 
The data on gynecological cancer cases diagnosed in adult women (age ≥15 
years) were retrieved from ECR according to ICD-10 codes (Table 2). Cancer 
sites, overall time periods of analyses, morphology and stage definitions are 
specified in Table 2. Years of diagnosis were divided into three seven-year 
periods (1996–2002, 2003–2009, 2010–2016) to estimate the time trends of 
case distributions and survival (different time periods were used in papers I–IV 
due to data availability). 
The ECR has collected data on stage at diagnosis since 1995. T, N and M 
stage according to current TNM (Union for International Cancer Control) 
classification is reported on clinical and pathological cancer notifications. Stage 
data is available in coded format only from 2012. Therefore, for the purposes of 
this study, TNM information was extracted from notifications, computerized 
and categorized into stage groupings based on the 7th edition of TNM or FIGO 
staging system (2009) (Table 2).  
Age groups were defined according to the specifics of the cancer site studied 
and differed across cancer sites.  
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Surgical treatment of corpus uteri cancer was classified based on the infor-
mation reported on cancer notification (paper I). All patients reported to have 
undergone surgical treatment, regardless of intention were considered as 
surgically treated. The passive nature of reporting did not allow to distinguish 
between “surgical treatment not done” and “surgical treatment not reported”, 
nor between types and intention of surgical treatment. 
The percentage of microscopically verified cases, the percentage of death 
certificate only cases and cases diagnosed at autopsy were considered as data 
quality indicators. 
 
4.2 Statistical methods 
Incidence, mortality and relative survival were estimated for corpus uteri, 
cervical, ovarian and vulvovaginal cancers. Age-period-cohort analysis was 
performed to distinguish the effects of age, period and cohort on cervical cancer 
incidence. Both corrected and uncorrected mortality trends were analyzed for 
corpus uteri and cervical cancer. 
 
Descriptive statistics 
Chi-square test and two-sided p-values were used to test the statistical signi-
ficance of the difference between proportions. P-value <0.05 was considered 
statistically significant. STATA 14.1 software (StataCorp LP, College Station, 
TX, USA) was used. 
 
4.2.1 Incidence 
The incidence rate was calculated by dividing the annual number of incident 
cases by the average annual number of the female population in a given year 
and expressed per 100 000 person-years. World standard population (1960) 
(Waterhouse et al., 1976) was used for calculating age-standardized rates. Join-
point analysis with Joinpoint Regression Program (version 4.1.1.1) from the 
Surveillance Research Program of the US National Cancer Institute (http:// 
surveillance.cancer.gov/joinpoint/) was used to model the rates and calculate the 
estimated annual percent change (APC) with 95% confidence intervals (95% 
CI) (papers I-III). The minimum number of joinpoints (straight line) was zero 
and the maximum number suggested by the program for the dataset was five. 
Permutation test was used to assess the statistical significance of the APCs, 
where APC is significantly different from zero at alpha=0.05. 
For paper IV, the crude incidence rate was calculated for women age 15–44 
as a three-year moving average and the statistical significance of the trend was 
estimated and analyzed with linear regression. Microsoft Excel 2010 and 
STATA 11.2 software were used. 
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Age-period-cohort analysis 
Cervical cancer incidence trends were separately analyzed with age-period-
cohort analysis as shown by Carstensen (Carstensen, 2007). The analysis 
discerns the effects of age, period and cohort on cancer incidence. 
In order to avoid age-period-cohort identification problems, arbitrary const-
raints were added to the model. 1935–1939 as a reference cohort was chosen. 
To evaluate the goodness of fit between models with different parametrization, 
Akaike Information Criterion (Akaike, 1974) was used. The age-function is 
shown as age-specific rates in reference cohort and adjusted for the period 
effect. The cohort function is a rate ratio relative to reference cohort and the 
period effects are a rate ratio relative to the age–cohort prediction (Carstensen, 
2007). 
For the age-period-cohort analysis, incident cases were aggregated into a 
five-year period and age groups. Due to small numbers, the cases younger than 
30 years and older than 79 years were excluded. Thus, the analysis included 10 
age groups (30–34…75–79), 9 periods (1970–1974…2010–2014) and 27 birth-
cohorts (1895–1899…1980–1984). For the age-period-cohort calculations the 
Epi package’s apc.fit function in R software (http://www.R-project.org) was 
used.  
 
4.2.2 Mortality 
The mortality rate was calculated by dividing the annual number of cancer 
deaths by the average annual number of the female population in a given year 
and expressed per 100 000 person-years. World standard population (1960) 
(Waterhouse et al., 1976) was used for calculating age-standardized rates. 
Joinpoint analysis with Joinpoint Regression Program (version 4.1.1.1) from the 
Surveillance Research Program of the US National Cancer Institute (http:// 
surveillance.cancer.gov/joinpoint/) was used to model the rates and calculate the 
estimated annual percent change (APC) with 95% CI. 
The certification problems of uterine cancer deaths i.e. causes of death recorded 
as “uterine cancer not otherwise specified (NOS)” may introduce problems in 
interpreting uterine cancer mortality (Loos et al., 2004; Weiderpass et al., 
2014). To correct for these errors, the reallocation rule suggested by Loos et al. 
was used for corpus uteri and cervical cancer mortality estimation, under the 
assumption that cause of death NOS was allocated at random and the proportion 
of NOS of all uterine cancers was ≤25% (Loos et al., 2004; Weiderpass et al., 
2014). Corrected mortality rates could be estimated from 1995, as the pre-
viously used Soviet causes of death classification did not allow to distinguish 
deaths due to uterine cancer NOS. 
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4.2.3 Survival 
The patients were followed for vital status from the date of diagnosis until the 
31st of December 2016 via linkage with the Estonian Population Register using 
unique personal identification numbers. The linkage was performed by the 
ECR. In case of death or emigration, the respective date was obtained. 
Relative survival ratios (RSR) with 95% confidence intervals (CI) were 
calculated as the ratio of the observed survival to the expected survival of the 
underlying general population. The latter estimate was calculated according to 
the Ederer II (Ederer et al., 1959) method using national life tables for the 
female population stratified by single year of age and calendar year. Death 
certificate only (DCO) cases and those diagnosed at autopsy were excluded 
from survival analyses. Patients who were diagnosed and died on the same day 
were included with one day of survival time. Cohort analysis was used to 
estimate RSRs for patients diagnosed in earlier periods (1996–2002, 2003–
2009). Period analysis was used for later cohorts not reaching 5 years of follow-
up from diagnosis during the studied period (2010–2016). The International 
Cancer Survival Standards were used for age-standardizing overall RSRs 
(Corazziari et al., 2004). All calculations were conducted with STATA 14.1 
(StataCorp LP, College Stations TX USA); survival analysis was performed 
using the strs module.  
 
 
4.3 Ethics 
The study protocol was approved by the Tallinn Medical Research Ethics 
Committee (Decision no. 284, May 16, 2013; Decision no 2636, February 14, 
2019). 
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5. RESULTS 
A total of 12 142 incident cases of gynecological cancer were diagnosed in 
adult women in Estonia in 1996–2016 (Table 3). 95% were microscopically 
verified cases. Death certificate only and autopsy cases comprised 1% of cases 
throughout the studied period.  
The most frequent gynecological cancer was corpus uteri cancer (35%), 
followed by cervical cancer (29%), ovarian cancer (27%) and vulvovaginal 
cancer (6%). Other gynecological cancers and cancers not otherwise specified 
comprised 2% of cases. During the three time periods (1996–2002, 2003–2009, 
2010–2016) the proportion of corpus uteri cancer increased from 34% in the 
earliest to 38% in the last period and ovarian cancer cases decreased from 28% 
in the earliest to 25% in the last period. Other gynecological cancer cases 
remained with unchanged proportions. Over the whole study period, 20% of 
cases were women under 50 years. The proportion of elderly women (age 80+ 
years) increased during the study period from 8% to 14%. 
The microscopic verification rate was lowest for other cancers (66%) and 
ovarian cancer (90%), while it exceeded 97% for all other sites. The age 
distribution of gynecological cancer incident cases varied by cancer types 
during the study period (Table 4). The majority of cervical cancer cases (64%) 
were diagnosed in women aged 60 years and younger while 57% of corpus uteri 
cancer cases and 51% of ovarian cancer cases were observed in women age 60–
79 years. The distribution of vulvovaginal cancer cases showed that 63% of 
incident cases were diagnosed in women aged 70 years and older (Table 4). 
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Corpus uteri cancer 
The incidence of corpus uteri cancer increased significantly from 1968 to 1998 
at a rate of 1.2% per year and from 2009 to 2016 at a rate of 2.8% per year 
(Figure 1).  
 
 
 
Figure 1. Observed (dotted line) and modelled (solid line) rates and annual percentage 
change (APC) for trends in age-standardized incidence (1968–2016) and corrected and 
uncorrected mortality (1994–2016) of corpus uteri cancer in Estonia. *The APC is 
significantly different from zero at alpha=0.05. 
 
 
Incidence remained stable for women younger than 65 years and increased for 
women age 65–74 years, and ≥75 years (paper I, Figure 1). The overall inci-
dence rate of corpus uteri cancer in young women aged 15–44 increased signi-
ficantly during 1980–2009 (p=0.023) (paper IV, Figure 2). Incidence increase 
was limited to cancer of type I morphology, while the incidence of cancers of 
type II or other morphology decreased (paper I, Figure 2). 
The uncorrected and corrected trends for corpus uteri mortality were slightly 
different, suggesting larger misclassification during earlier years. In general, 
age-standardized mortality remained stable (Figure 1). Mortality remained un-
changed for all age groups below 75 years but increased at a rate of 1.6% per 
year for women age ≥75 years (paper I, Figure 1). 
The proportion of stage II cases decreased significantly from 11% to 7% in 
1996–2016 and stage IV declined from 11% to 8%, respectively. Surgical treat-
ment became significantly more frequent comparing the earliest (1996–2002, 
85%) to the latest (2010–2016, 89%) study period (paper I, Table 1). The pro-
portion of surgically treated patients increased the most for elderly patients 
(from 58% to 79% in age group 75 years), and for stage IV (from 49% to 
65%) and stage III (from 86% to 95%) (paper I, Table 3). 
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The overall age-standardized 5-year RSR significantly improved during the 
study period 1996–2016 and reached 78% in 2010–2016 (Table 5). The survival 
increased for all age groups and the age gap narrowed as the largest increase 
was seen in patients age 65 and older (paper I, Table 2). Survival increase was 
seen for all stages, but significant improvement was observed only in stage IV 
patients (paper I, Table 2).  
 
 
Table 5. Age-standardized 5-year relative survival ratio (RSR) for gynecological 
cancers in Estonia, 1996–2016 
 1996–2002 2003–2009 2010–2016  
 5-year 
RSR  
95% 
CI
5-year 
RSR 
95% 
CI
5-year 
RSR 
95%  
CI Change
a 
Corpus uteri 71 67–74 71 67–74 78 76–81 +7 
Cervix 60 57–63 66 63–69 66 63–68 +6 
Ovary 29 26–32 36 33–39 44 40–47 +15 
Vulvovaginal 55 47–61 61 53–69 61 53–68 +6 
a From first to last period; statistically significant findings in bold 
 
 
Cervical cancer 
The incidence of cervical cancer decreased significantly until 1980 and in-
creased thereafter until the end of the study period at a rate of 0.6% per year 
(Figure 2).  
 
 
 
Figure 2. Observed (dotted line) and modelled (solid line) rates and annual percentage 
change (APC) for trends in age-standardized incidence (1968–2016) and corrected 
(1994–2016) and uncorrected (1984–2016) mortality of cervical cancer in Estonia. *The 
APC is significantly different from zero at alpha=0.05. 
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Significant incidence increase since the 1990s was observed for all age groups 
except 70+ years (paper II, Figure 1). In women age 15–44, the overall cervical 
cancer incidence rate increased significantly in 1980–2009 (paper IV, Figure 1). 
The age-period-cohort analysis showed a continuous increase in the relative risk 
of cervical cancer for all birth-cohorts younger than those born in 1940 (paper 
II, Figure 2). No period effects were seen. 
The significant increase in squamous cell carcinoma incidence from 1980 
was accompanied by a significant increase in adenocarcinoma incidence from 
the late 1990s (paper II, Figure 1).  
The proportion of stage I cancers decreased from 40% in 2005–2009 to 35% 
in 2010–2014, while the proportion of stage IV increased from 13% in 2005–
2009 to 18% in 2010–2014 (paper II, Table 1). 47% of all cases were observed 
in women aged 40–59 years. The proportion of incident cases of adenocarci-
noma histology increased from 6% in 1995–1999 to 14% in 2010–2014. Squa-
mous cell carcinoma cases decreased from 85% in 1995–1999 to 78% in 2010–
2014 (paper II, Table 1). The shift towards later stages was observed for all age 
groups except women aged 40–49 years (paper II, Figure 2). The proportion of 
stage I cases decreased from 40 to 35% (p=0.0096) and the proportion of stage 
IV cases increased from 13 to 18% (p=0.0019) (paper II). 
The overall age-standardized mortality trend for cervical cancer showed a 
modest decline by APC 1.3% (uncorrected) from 1985 to 2016 (Figure 1). The 
corrected mortality trend from 1995 to 2016 mimicked the longer uncorrected 
pattern with a slightly more prominent decline by APC 1.6% per year. Stable 
trends were observed for the age groups of 15–29 years, 40–49 years and 50–59 
years. The significant declining mortality trend for women aged 60–69 years 
and 70+ years was observed (paper II, Figure 1). 
The age-standardized 5-year RSR of cervical cancer patients increased 
significantly from 1996 to 2009 and stabilized thereafter and estimated at 66% 
in 2010–2016 (Table 5). The significant improvement was seen in the age 
groups of 30–39 and 40–49 (paper II, Table 2). In the oldest age group the 5-
year RSR slightly decreased. 
 
Ovarian cancer 
The incidence of ovarian cancer has been stable over the study period 1968–
2016 (Figure 3). For the age group of 50–59 years a significant decline by APC 
3.4% per year was observed from 1995 to 2009 and followed by a significant 
increase until 2013 (paper III, Figure 1). Incidence rates for all other age groups 
have been stable. No significant changes in incidence were seen in women age 
15–44 in 1980–2009 (paper IV, Figure 3). 
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Figure 3. Observed (dotted line) and modelled (solid line) rates and annual percentage 
change (APC) for trends in age-standardized incidence (1968–2016) and mortality 
(1994–2016) of ovarian cancer in Estonia. *The APC is significantly different from zero 
at alpha=0.05. 
 
 
The distribution of cases by age groups showed a decrease in the proportion of 
women aged 50–69 years and an increase in the proportion of women ≥70 
years, the latter counting 42% of all cases in 2005–2009 (paper III, Table 1). An 
increase in the proportion of stage I disease from 14% in 1995–1999 to 16% in 
2005–2009 was observed, while stage III and stage IV cases increased from 
64% to 67% over the study period. 
The overall mortality rate has been significantly declining since 1995 by 
APC 2.2% per year (Figure 1). A significant mortality decline was seen in the 
age groups of 50–59 and 60–69, while no changes were seen in the age group of 
15–49 and a fluctuating trend was seen for the age group ≥70 with a significant 
decreasing segment from 2009 (paper III, Figure 1). 
Ovarian cancer age-standardized RSR has significantly improved from 29% 
in 1996–2002 to 44% in 2010–2016 (Table 5). The survival has increased in all 
age groups and in all stages (paper III, Table 2). 
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Vulvar and vaginal cancers 
The age-standardized incidence rate of vulvovaginal cancer has been stable over 
the study period, while mortality has declined by 1.0% per year since 1996 
(Figure 4).  
 
 
 
 
Figure 4. Observed (dotted line) and modelled (solid line) rates and annual percentage 
change (APC) for trends in age-standardized incidence (1968–2016) and mortality 
(1994–2016) of vulvovaginal cancer in Estonia. *The APC is significantly different 
from zero at alpha=0.05. 
 
 
The stable trend was observed for both the younger and older age groups 
(Figure 5). 
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Figure 5. Observed (dotted line) and modelled (solid line) rates and annual percentage 
change (APC) for trends in truncated and crude age-standardized incidence (1968–
2016) by age of vulvovaginal cancer in Estonia. *The APC is significantly different 
from zero at alpha=0.05. 
 
 
The proportion of the youngest age group 15–49 developing vulvovaginal cancer 
has decreased and the oldest age group has increased during the studied period 
1996–2016 (Figure 6). 
The age-standardized 5-year RSR has increased from 55% in 1996–2002 to 
61% in 2003–2009 and has been stable thereafter (Table 5). 
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Figure 6. The age distribution of incident cases of vulvovaginal cancers, 1996–2016 
(p=0.053) 
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6. DISCUSSION 
This thesis provides an in-depth analysis of the long-term trends of all gyneco-
logical cancers in Estonia, using a variety of statistical methods. Incidence 
trends were examined over four decades, and mortality and survival trends over 
two decades. We observed a significant increase in the incidence of the two 
most common gynecological cancers, corpus uteri and cervical cancer. The 
trend for the latter site reflected the risk increase in successive birth cohorts 
born after the 1940s with no health-care related period effects to counteract 
those strong cohort effects. No particular changes were seen in the incidence of 
ovarian and vulvovaginal cancers. A significant mortality decrease has been 
apparent for ovarian cancer over the whole study period and for cervical cancer 
in more recent years. The largest survival improvement was seen for ovarian 
cancer (15% units over 20 years), while the progress was less rapid for other 
cancers. The proportion of older women among gynecological cancer patients 
almost doubled during the study period. A slight shift towards earlier diagnosis 
was seen only for corpus uteri cancer, whereas the stage distribution of cervical 
cancer shifted significantly towards the later stage. 
 
Strengths and weaknesses of the thesis 
The thesis is the first comprehensive overview of the long-term trends of 
gynecological cancers in Estonia. The main strength of the study was the use of 
uniformly collected population-based incidence data from the cancer registry 
that has nation-wide coverage since 1968 and adheres to international rules and 
principles, allowing specific analyses by morphology. The good quality of ECR 
data in terms of completeness, validity and vital status follow-up is evidenced 
by several quality analyses and international projects. The validity of ECR data 
is comparable to European cancer registries’ estimates (Innoset al., 2015; Oru-
maa et al., 2015). The quality indicators (percentages of microscopically veri-
fied cases, autopsy cases and death certificate only cases) were similar to other 
registries in Western Europe (Innos et al., 2015; Orumaa et al., 2015). As an 
additional strength, data on tumor stage was available for a 20-year period. The 
study used a variety of statistical methods to better characterize changes over 
time and generations (i.e. join-point regression, age-period-cohort analysis) and 
took specific measures to overcome possible problems with data quality (i.e. 
corrected mortality analysis). 
The main weakness of the study was limited information on the predictors of 
incidence or survival. Individual data on socioeconomic background, obstetrical 
status, place of residency or average income of women were not available for 
analysis. The data on performed hysterectomies and the detection mode of 
cervical cancers (screen-detected or not) were not available either.  
Mortality analyses were limited by data availability and the use of a Soviet 
coding system used prior to the adoption of the ICD in 1995, which did not 
allow to distinguish several disease entities. Therefore, the time periods 
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included in mortality trend analyses differed across cancer sites and corrected 
mortality analysis for corpus uteri and cervical cancer was only possible from 
1995. The comparison of uncorrected and corrected mortality rates demon-
strated larger misclassification in earlier years, supporting the need for pre-
senting corrected rates in order to avoid inaccurate interpretations of mortality 
trends. Furthermore, an evaluation of cause of death misclassification using 
linkage of individual incidence and death records is warranted in order to obtain 
a more precise estimate of the magnitude of possible misclassification. This 
study is ongoing. 
Trends by histological types may have been influenced by the continuously 
improving accuracy of pathological diagnosis that has brought along lower pro-
portions of NOS diagnoses and less misdiagnosis over the study period. Like-
wise, more thorough diagnostic work-up and the use of more accurate diagnos-
tic methods in the later periods may have caused stage migration and led to 
some overestimation of stage-specific survival estimates. 
 
Corpus uteri cancer 
Corpus uteri cancer has become the most common gynecological cancer in 
Estonia. Its two types showed the distinct incidence trends. The rapid increase 
of type I endometrial cancer has been observed in developed countries and the 
main reason is considered to be the burden of obesity (Evans et al., 2011; 
Onstad et al., 2016). Being overweight and obese are increasing in Estonia 
(Tervise Arengu Instituut, 2018.) and this has likely contributed to the increase 
of the overall corpus uteri cancer incidence. The increase is more prominent in 
women aged over 65 years and an incidence increase driven by the same age 
group has also been observed in the Netherlands (Boll et al., 2013). Still, the 
trends in incidence are not consistent in all countries. In Denmark, overall 
decrease of corpus uteri cancer has been shown and the decrease of type I 
cancers was accompanied by the increase of type II cancers (Faber et al., 2017). 
The decline of the age-standardized incidence rate and the proportion of type II 
cancers in Estonia could reflect the possible misclassification of serous tumors 
during earlier periods. More accurate pathological diagnostics, e.g. immuno-
histochemistry, may detect more precisely the origin of the cancer. 
The other possible underlying reasons for the increasing corpus uteri cancer 
trend in Estonia are the decrease of the number of children and deliveries per 
women. The average number of children per woman in 2018 was 1.7 (Statistics 
Estonia, 2019). The number of children per woman has been decreasing over 
time. For today’s 55–59 years old women the mean number of children is 1.9 
and for women 40–44 it is 1.7. The mean age at first birth has also risen from 
22.7 years in 1992 to 28.3 years in 2017 (National Institute for Health Devlop-
ment, 2019).  
The use of menopausal HRT is not common among Estonian women (Sam-
mul et al., 2018). HRT with estrogen compound only is permitted for women 
without a uterus and its use among women is very low. 
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The stage distribution with the increased proportion of stage I disease 
suggest more frequent early detection. The data is consistent with the type I 
cancers’ clinical behavior which could be detected at an early stage due to the 
occurred symptoms.  
The overall stable mortality trend of corpus uteri cancer is in line with most 
European countries’ estimates (Weiderpass et al., 2014). However, more atten-
tion should be paid to the cause-of-death data among endometrial cancer 
patients in Estonia. Endometrial cancer patients might suffer from several co-
morbidities that could be life-limiting besides cancer itself. Comorbidities are 
frequently related to obesity e.g. hypertension and diabetes. Diabetes and two or 
more comorbidities are found to be negative predictors for corpus uteri cancer 
mortality (Nagle et al., 2018). Cardiovascular disease is the main cause of death 
for both younger and older patients with localized endometrial cancer (Ward et 
al., 2012). Type II cancers cause the most cancer related deaths among corpus 
uteri cancers (Torre et al., 2017; Ward et al., 2012). Therefore, the possible 
misattribution of cause of death could be suspected, considering the data on 
histological subtypes and stages. 
Despite the significant improvement of corpus uteri cancer survival observed 
during the study period, the latest 5-year RS estimate of 78% is still lower than 
the estimate in the US (81%) in 2009–2015 (National Cancer Institute, 2019) 
and in the Nordic countries (83%) (Danckert et al., 2019) during the same 
period. The gap mostly remains for women age 65 and over, although this age 
group experienced the largest survival improvement. Large survival increases 
for both elderly women and stage IV patients occurred in parallel with a large 
increase in the proportion of patients treated surgically. 
More frequent surgeries during the study period among elderly women could 
refer to better management of comorbidities. Even at late stages, surgical 
treatment is found to increase the survival for corpus uteri cancer patients 
(Barlin et al., 2010). The significant increase of surgically treated corpus uteri 
cancer patients during the past 20 years have also been observed in Norway 
(Trovik et al., 2012). The increasing surgery rate might be somewhat consistent 
with higher proportions of stage I disease which are frequently clinically 
managed by surgery only. However, comparing the data with the Norwegian 
95% of patients who had undergone surgical treatment in 2001–2010 (Trovik et 
al., 2012) and the estimate found in the thesis which was only 89% in the last 
studied period, the need for the improvement in clinical care should be realized. 
 
Cervical cancer 
The increase in cervical cancer incidence with the shift towards later stages and 
older ages reflects the ineffectiveness of the nation-wide screening program in 
Estonia which was established in 2006 (Lynge et al., 2017). An effective 
screening program would have been expected to result in fewer cancer cases 
and the shift towards earlier stages and ages (Dickinson et al., 2012; Serraino et 
al., 2015). The major interventions made by countries e.g. nation-wide 
screening programs, have shown clear positive changes in the epidemiological 
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trends of cervical cancer in terms of the relative risk reductions in cervical 
cancer incidence by birth-cohorts and the decrease in incidence rates (Lynge et 
al., 2017; Vaccarella et al., 2013). The age-period-cohort analysis performed in 
the thesis showed the peak incidence in cervical cancer diagnosis around 50 
years and a constantly increasing risk for all birth-cohorts from women born in 
1940. No period effects were apparent. In the Nordic countries, more than 50 
years of cervical cancer screening has set the peak incidence appearance around 
the age of 30 (Lynge et al., 2017; Serraino et al., 2015). This is the time when 
the first screening tests have been given by the first target age group. The 
increasing prevalence of HPV and changed sexual behavior have put birth-
cohorts of women born after 1940 at an increasing risk of cervical cancer. This 
manifestation is common for all European countries (Vaccarella et al., 2014; 
Vaccarella et al., 2013). The period effect has shown a large decreasing cervical 
cancer incidence trend from the 1960s in the Nordic countries (Vaccarella et al., 
2014). This is consistent with the beginning of screening in these countries. Our 
analysis showed a constantly stable period effect which refers to the lack of 
effective interventions against cervical cancer, including an opportunistic or 
organized screening program. It has been estimated that the screening program 
in the Nordic countries has prevented around 50% of cervical cancer cases from 
the beginning of the 1960s.  
The high participation rate in organized screening programs is the corner-
stone of a successful screening. In Denmark a stable participation rate of 75% in 
2009–2015 was concluded as the reason for having one of the highest cervical 
cancer incidence rates (10/100 000, world) in the Nordic countries (Danckert et 
al., 2019; Lynge et al., 2017). The participation rate in Sweden has been 80% 
and the incidence rate is estimated at 9/100 000 (world) (Ferlay et al., 2018). In 
Estonia, the high incidence rate of 22/100 000 (world), reflects the low 
participation rate of the target population that has been estimated at only 51% in 
2017 and even lower earlier (National Institute for Health Development, 2019). 
The nation-wide screening covers women with valid health insurance. In 2018, 
less than 95% of the Estonian population had valid health insurance (Organisa-
tion for Economic Co-operation and Development, 2019). Therefore, for the 
purposes of cervical cancer incidence decline in Estonia, women without health 
insurance should be included into the screening. The Nordic countries data have 
shown the second incidence peak among the elderly, women over 70 years old 
(Lynge et al., 2017). It is considered to be related to screening activities which 
were completed too early (aged 55). Therefore, the need to broaden the age 
frame up to the age of 70 years should be taken into account also in Estonia. For 
the strengthening of screening impact on cervical cancer incidence and survival, 
the addition of HPV-DNA detection besides the conventional Pap-smear test 
must be considered. Women with high risk HPV types need more frequent 
follow-up and accurate management. 
In the thesis the corrected mortality showed a slightly decreasing trend from 
1995 when even the rate above 4/100 000 per year is relatively high. In most of 
the European countries the mortality of cervical cancer is in a continuous 
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decline (Arbyn et al., 2009). In certain Eastern European countries, the trend 
has shown a stable or even an increasing pattern. Mortality rates are compatible 
with incidence rates. In countries with increasing or stable mortality rates, the 
cervical cancer screening is not working or is not established at all (Anttila et 
al., 2009; Lynge et al., 2017). 
The aim of Pap-smear based screening is to prevent cervical cancer by 
treating premalignant lesions or find the cancer early when the cure is possible. 
It is estimated that Estonia would face an extra 1500 cervical cancer deaths by 
2030 (Vaccarella et al., 2016) if strong preventive input won’t be considered. 
From 2018 the vaccination of girls aged 12–14 has been integrated into the 
national vaccination plan. The decrease of pre-malignant cervical lesions and 
genital warts can be expected in 10 years (Drolet et al., 2015). 
For the period 2010–2016, the 5-year RSR in Estonia was estimated at 66%. 
This is comparable to Nordic data during the same period 2012–2016 (Danckert 
et al., 2019) – 66% in Finland and the highest estimate of 73% in Norway. In 
Estonia, the significant improvement in survival from 1995–1999 to 2010–2016 
was accompanied by dismal incidence rate, age and stage distributions. 
The halted overall survival improvement in the later period of 2010–2016 
reflects the shift towards later stages, but the small progress in implementing 
modern treatment modalities could also be considered. The conclusions of a 
clinical audit performed by EHIF in 2014–2015 referred to the limited availabi-
lity of radiotherapy for cervical cancer patients. Furthermore, the new systemic 
treatments should be made available faster for patients suffering from cervical 
cancer.  
 
Ovarian cancer 
Stable incidence, significantly decreased mortality and rapidly increased survi-
val of ovarian cancer patients have been observed in the thesis.  
The long-time decline of ovarian cancer incidence has been observed in 
developed countries (Lowe et al., 2013; Sopik et al., 2015) and it is considered 
to be related to widespread oral contraceptive use which have a protective role 
against the cancer (Sopik et al., 2015). In the US approximately 85% of women 
born later than 1940 have used oral contraceptives at some period of their lives 
(Sopik et al., 2015). The real effect of oral contraceptives use on ovarian cancer 
incidence in Estonia could be expected within 10 years as the protective effect 
of the drugs lasts up to 30 years if ever used (Collaborative Group on Epidemio-
logical Studies of Ovarian Cancer, 2008; Webb et al., 2017). The protective role 
of pregnancies could be considered, observing a significant incidence decline in 
the age group 50–59. The baby-boom took place in Estonia at the end of the 
1980s and in the beginning of the 1990s. These women were at child-bearing 
age at that time which may have affected their cancer risk. The stage distri-
bution of ovarian cancer over the studied period of 1995–2009 did not show any 
major changes. According to these findings no improved early detection could 
be concluded. As the ovarian cancer age-adjusted incidence rate increases with 
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age, the growing proportion of women over 70 years is the consequence of an 
ageing population. 
The mortality of ovarian cancer has significantly declined in Estonia. Stable 
overall incidence trend and improved access to specialized care are the pro-
posed reasons for better mortality estimates.  
The overall survival of ovarian cancer has significantly improved from 1996 
to 2016. The 5-year RSR of 26% observed in the EUROCARE-3 study has 
almost doubled by 2010–2016 reaching 44%. The estimate is highly comparable 
with countries with high quality cancer care like the Nordic countries (Danckert 
et al., 2019). The data on 5-year RSR on ovarian cancer survival in 2012–2016 
showed 49% in Sweden, 45% in Norway, 44% in Finland and 41% in Denmark.  
The progress in medicine has improved ovarian cancer patients’ short-term 
survival, but the long-term survival has not improved in the world. Approxima-
tely 80% of ovarian cancer patients die due to the cancer within 10 years and 
only 13% are alive with advanced stages at 10 years from diagnosis (Timmer-
mans et al., 2018). 
The importance of optimal cytoreduction with no residual disease left in the 
advanced stages were introduced in the world in the beginning of the 2000s 
(Aletti et al., 2006; Du Bois et al., 2009) and it has remained the most powerful 
prognostic factor for ovarian cancer survival. Platinum-based chemotherapy, 
introduced in the beginning of the 1980s by cisplatin and replaced by 
carboplatin in the beginning of the 2000s, added an additional survival benefit 
and raised the overall 5-year RSRs over 4 years for advanced stages (Ozols et 
al., 2003). Today, maintenance therapy and evolving personalized medicine are 
expected to improve survival further (Mirza et al., 2018.).  
Extensive surgeries with wide excisions and the management of postopera-
tive complications could be performed only in high volume and well-equipped 
specialized hospitals. The audit in four hospitals performing ovarian cancer 
surgical treatment were carried out in 2014–2015 in Estonia. The audit was 
managed by the EHIF. The overall conclusion of ovarian cancer surgical treat-
ment was good, and 79% of patients had undergone optimal cytoreduction. 
More efforts and unification were suggested for early stage surgical treatment 
(Eesti Haigekassa, 2019).  
 
Vulvovaginal cancer 
The incidence of vulvovaginal cancer showed a fluctuating trend from 1968 to 
2016 due to a small number of cases, while mortality did not change signi-
ficantly in 1995–2016. The increase of vulvovaginal cancer incidence has been 
previously observed in Germany and in England (Holleczek et al., 2017; Lai et 
al., 2014). The incidence increase in these countries has been significantly 
based on the increasing incidence among women under 60 years old. The 
proportion of women 54 years and younger diagnosed with vulvar cancer has 
increased from 11% in 1989–1993 to 23% in 2009–2013 in Germany (Holle-
czek et al., 2017). In contrast the proportion of elderly women 75 years and 
older has decreased from 44% to 35% during the same period. The increase in 
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the number of overall cases were also observed. In this thesis, contrary to 
German trends, the number of cases during the studied period did not change 
and the proportion of women 70 years and older increased from 57% in 1996–
2002 to 65% in 2010–2016 and the proportion of younger women aged 60 years 
and less, decreased from 19% to 14% during the same period. The observed age 
standardized incidence rates in Estonia have been stable for both younger and 
older women. The increase of the incidence among younger women has been 
explained by the widespread prevalence of HPV and its cancerous type 16 
(Barlow et al., 2015) as the main risk factor. The incidence pattern observed in 
the thesis over the study period might refer to a smaller prevalence of high-risk 
HPV type 16 among middle-age women than among the counterparts in 
countries with higher incidence rates.  
The estimated stable mortality trend refers to stable and unchanged inci-
dence trends. 
The stable survival rates during the latest periods (5-year RSR in 2003–2009 
and 2010–2016, respectively) were lower than the estimates in the Nordic 
countries (Danckert et al., 2019.), England (Lai et al., 2014) and in Germany 
(Holleczek et al., 2017). The rise in detection of early stage tumors in concor-
dance to the incidence increase of younger women have been described in these 
countries. Treatment at earlier stages has a more favorable outcome in terms of 
overall survival. High proportions of elderly patients with more advanced 
tumors could be the reason for dismal overall survival in Estonia.  
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7. CONCLUSIONS 
The thesis provides a comprehensive overview of long-term gynecological 
cancer incidence, mortality and survival trends in Estonia that reflected the 
societal and economic transition in the country during the past decades. The 
results of the study identified a major pitfall in cancer control in Estonia by 
revealing dismal cervical cancer trends resulting from an underpowered national 
cervical cancer screening program. The changing risk factor profile cannot be 
underestimated in the increasing incidence trend of corpus uteri cancer and also 
cervical cancer. Women’s health issues should be of high importance in the 
state health policy and women’s cancer prevention and early detection should 
be highlighted in cancer control.  
The results of the thesis contribute to evidence-based health policy by 
helping to define the future perspective in women’s cancer and giving the 
directions for the improvement in health care organization, public health 
policies and cancer care. 
1. Corpus uteri cancer is the most frequent gynecological cancer in Estonia. 
The incidence of corpus uteri cancer has increased driven by the type I 
cancer trend. The most likely underlying cause of the trend is the increasing 
prevalence of obesity in female population. The observed survival increase 
was most likely associated with more frequent surgical treatment among all 
age groups and stages. The importance of the management of comorbidities 
for corpus uteri cancer outcomes is widely recognized, therefore the 
improvement in the management of comorbidities, especially at older ages 
would lead to further survival gain. Corpus uteri cancer mortality has not 
turned to a decline.  
2. The study demonstrated increasing cervical cancer incidence rates in women 
under 70 years of age. Increases were seen for both major histological 
subtypes. The overall rising incidence trend reflected the increasing risk in 
successive birth cohorts born after 1940s with no interventions to counteract 
this. The corrected mortality trend showed a modest decline while mortality 
rate remained high. Although cervical cancer survival has somewhat im-
proved, the observed shift towards older ages and later stages is not consis-
tent with the outcomes expected from ongoing nation-wide screening. 
3. The incidence of ovarian cancer has been stable over the past decades in 
Estonia. The rapid mortality decline was accompanied by significant im-
provement of survival, which has now reached estimates comparable with 
European countries of high-quality cancer care. The pattern was even more 
remarkable if considering the increased proportion of elderly women and the 
survival gain both in elderly women and most advanced stages.  
4. A stable incidence trend of vulvovaginal cancer was shown over the study 
period. No shift towards younger ages or the increase in the incidence of 
younger women was observed. The stable mortality rates and only modestly 
improved survival indicate the need to pay more attention to elderly women.  
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8. IMPLICATIONS FOR PRACTICE 
Corpus uteri cancer 
The country’s public health strategy for tackling obesity should incorporate 
measures for increasing awareness about obesity related cancers, including 
endometrial cancer in women, among other health problems. Clinicians should 
put more effort into advising overweight and obese women. The detection and 
consideration of the patient’s individual risk factors would lead to tailored 
diagnostics of suspicious premalignant conditions and more frequent early 
detection of corpus uteri cancer. The implementation of relevant guidelines for 
early detection and optimal management of endometrial hyperplasia to prevent 
corpus uteri cancer should be emphasized. The prevention and treatment of 
comorbidities (diabetes, cardiovascular disease) are essential for longer survival 
and for the ability to apply different treatment modalities to endometrial cancer 
patients. 
 
Cervical cancer 
The trends found in the study are similar to other Eastern European countries 
and lead to the conclusions that the Pap-smear-based screening strategy has 
been ineffective. There is an urgent need to acknowledge that screening acti-
vities must be improved. The participation rate needs to be increased. Quality 
assurance measures have to be implemented in the program. Opportunistic 
screening should be replaced by program-based activities. Further activities and 
a follow-up in case of an abnormal Pap-smear finding are of the greatest 
importance in preventing cervical cancer. The addition of HPV-DNA detection 
could help to detect women with high risk lesions and plan specific treatment 
and follow-ups. Upper age limit for screening should be increased. Home-
testing should be offered to women who have not participated for more than 7 
years in screening. Women without health insurance are the highest risk group 
for cervical cancer and therefore must be included into the screening. More 
accurate data and feedback on participation, Pap-smear results and screening 
service providers should be gathered in Estonia. Regular monitoring of quality 
indicators for screening activities might help to define possible pitfalls in data 
accuracy and timely adequacy. Altogether, both the strengthening of screening 
activities and treating cervical cancer patients should be addressed. HPV 
vaccination for girls started in 2018 and the results in terms of cervical cancer 
incidence decrease could be expected no earlier than in 10 years. The data on 
vaccination should be registered on individual level that would help to adapt 
further screening. Vaccination of boys against HPV should be considered. 
 
Ovarian cancer 
New approaches are needed to reduce ovarian cancer incidence, improve early 
detection and prolong survival. Genetic counselling and prevention should be 
emphasized as the only effective prevention strategy for hereditary ovarian 
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cancer. Implementation of new treatment modalities both in surgery and in 
systemic therapy are essential for better survival outcomes. Collaboration in 
clinical and scientific projects with hospitals and institutions together with 
neighboring countries would bring benefit for both patients and clinicians. The 
timely access to high quality care is the key prerequisite for better outcomes.  
 
Vulvovaginal cancer 
The importance of the follow-up and treatment of lichen sclerosus and low-risk 
VIN are important to reduce vulvar cancer incidence in Estonia. Elderly women 
should be informed about vulvar cancer symptoms and about the need to visit a 
gynecologist regularly. Taking into account the trends of cervical cancer as 
HPV induced cancer, vigilance regarding the increasing incidence of vulvo-
vaginal cancer in younger women should be kept in mind by clinicians in 
future. Regular gynecological check-ups and the knowledge about the symp-
toms of vulvovaginal cancer should be emphasized to achieve earlier detection. 
Tackling and preventing health problems caused by HPV should be the focus in 
the future. 
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9. FUTURE DIRECTIONS 
The continuous evaluation of gynecological cancer trends is necessary for 
cancer control and health policy implementation. Further studies should take 
into account individual data on the place of residence, average income and the 
level of education to study relevant associations. As cancer treatment might 
result in major disabilities, the quality of life of gynecological cancer patients 
needs to be studied and improved.  
More in-depth research on corpus uteri cancer incidence and mortality 
should be carried out to describe the influence of risk factors and the presence 
of co-morbidities. Mortality trend needs to be re-evaluated by taking into 
account all-cause mortality and disease specific mortality. The evaluation of 
different treatment modalities would have an important value in planning cancer 
care. 
Cervical cancer incidence trend reflects the ineffectiveness of nation-wide 
screening program. Therefore, the studies on incidence and mortality trends are 
needed to improve the screening program. Further studies should take into 
account the woman’s participation in screening, previous Pap-smear test results 
and socioeconomic background. 
Ovarian cancer is a heterogeneous disease and the analysis of incidence 
trends of distinct subtypes’ with the consideration of known risk factors should 
be carried out. Hereditary ovarian cancer prevention should become of more 
interest in further studies. The evaluation and the prevention of hereditary 
ovarian cancer are important topics to discuss in near future in Estonia. 
Vulvovaginal cancer incidence is expected to rise in the future. The study on 
incidence rates among younger women with the assessment of the prevalence of 
different HPV types would give more information and the insight of future 
perspective. 
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SUMMARY IN ESTONIAN 
Günekoloogiliste pahaloomuliste kasvajate  
epidemioloogia Eestis 
Rahvastiku vananemine on toonud kaasa vähihaigestumuse tõusu üle kogu maa-
ilma. Arenenud riikides on vähk surmapõhjusena tõusnud sageduselt teisele 
kohale südame-veresoonkonna haiguste järel. Vähihaigestumuse, -suremuse ja  
-elulemuse mõõtmine on oluline vähitõrje ja tervishoiukorralduse planeerimi-
seks ja tõhususe hindamiseks.  
Naised moodustavad poole maailma elanikkonnast. Noorte naiste hulgas on 
haigestumus pahaloomulistesse kasvajatesse oluliselt kõrgem kui noorte meeste 
hulgas. Naiste vähist tingitud enneaegsete surmade vältimine ja tervisekao 
vähendamine on vähitõrje oluline eesmärk kogu maailmas. 
Günekoloogiliste paikmete vähid moodustavad kõigist naistel diagnoosi-
tavatest pahaloomulistest kasvajatest Euroopas 15% ja Eestis 13%. Munasarja-, 
emakakeha-, emakakaela-, häbeme- ja tupevähi riskitegurid erinevad ning nende 
paikmete kasvajate esinemist mõjutavad ühtlasi muutused ühiskonnas, sotsiaal-
majanduslikus seisundis ja tervishoiukorralduses. Eelnevad uuringud on Eestis 
näidanud kõrget haigestumust ja suremust günekoloogilistesse kasvajatesse ning 
Euroopa keskmisest madalamat elulemust.  
Emakakehavähi peamiseks riskiteguriks on ülekaal ja rasvumine. Selle kas-
vaja haigestumus on viimastel aastakümnetel maailmas tõusnud, suremus aga 
langenud või püsinud stabiilsena. Üleeuroopalise vähielulemusuuringu EURO-
CARE andmetel oli aastatel 2000–2007 emakakehavähi patsientide elulemus 
Eestis Euroopa viimase kolme kõige madalama tulemuse hulgas. 
Emakakaelavähi peamine riskitegur on seksuaalsel teel leviv inimese papil-
loomiviirus (HPV). Emakakaelavähki on võimalik ennetada riiklikul tasandil 
organiseeritud sõeluuringuga. Euroopas, välja arvatud Ida-Euroopa riikides, on 
täheldatud emakakaelavähi haigestumuse pidevat langust. Eestis on emaka-
kaelavähi haigestumus aga üks kõrgemaid Euroopas. Selle vähipaikme elulemus 
Eestis on Euroopa keskmisel tasemel.  
Munasarjavähi kõrge risk on peamiselt seotud geneetilise eelsoodumusega 
ning kaitsvaks teguriks on suukaudsete rasestumisvastaste vahendite kasuta-
mine. Viimastel aastakümnetel on maailmas täheldatud haigestumuse langust, 
suremus on aga stabiilne või langemas. Munasarjavähi elulemus on võrreldes 
teiste günekoloogiliste kasvajatega madal. Üleeuroopalised vähielulemusuurin-
gud on näidanud teatavat elulemuse paranemist, kuid viie aasta suhteline elule-
mus ei ole ületanud 50%.  
Häbeme- ja tupevähi peamiseks riskiteguriks on samuti HPV. Vanematel 
naistel võib häbemevähk areneda ka naha krooniliselt põletikulisest seisundist – 
lichen sclerosusest. Häbeme- ja tupevähi haigestumus on maailmas püsinud 
stabiilsena ning suremus on üldiselt madal. Häbeme- ja tupevähi elulemus on 
Euroopas viimastel kümnenditel paranenud.  
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Töö eesmärk 
Töö peamine eesmärk oli paremini mõista günekoloogiliste pahaloomuliste 
kasvajate pikaajalisi haigestumuse, suremuse ja elulemuse trende Eestis, hin-
nates neid ühiskonnas aset leidnud sotsiaalsete ja tervishoiukorralduslike muu-
tuste, riskitegurite trendide ja emakakaelavähi sõeluuringu kontekstis. 
Töö alaeesmärgid: 
1. Hinnata emakakehavähi haigestumust, suremust ja elulemust Eestis, kesken-
dudes vanusele, staadiumile, histoloogilisele alatüübile ja kirurgilisele ravile. 
2. Analüüsida emakakaelavähi haigestumust, suremust ja elulemust Eestis 
vanuse, staadiumi ja histoloogilise alatüübi järgi, rõhuasetusega sünni-
kohordi- ja perioodiefektidel. 
3. Hinnata munasarjavähi haigestumust, suremust ja elulemust Eestis vanuse ja 
staadiumi järgi. 
4. Kirjeldada häbeme- ja tupevähi haigestumust, suremust ja elulemust Eestis. 
 
Materjalid ja metoodika 
Töö peamise andmeallikana kasutati Eesti Vähiregistrit. See on rahvastiku-
põhine register, mis kogub andmeid kõigi Eestis diagnoositud vähijuhtude 
kohta. Register loodi 1978. aastal ja sisaldab andmeid alates 1968. aastast. And-
med surmajuhtude kohta saadi Eesti Surmapõhjuste Registrist ja rahvastiku-
andmed Statistikaametist. 
Andmed täiskasvanud naistel (vanus ≥15 aastat) diagnoositud günekoloogi-
liste pahaloomuliste kasvajate kohta koguti vähiregistrist vastavalt Rahvusvahe-
lise Haiguste Klassifikatsiooni (RHK) 10. versioonile. Histoloogilised tüübid 
defineeriti RHK Onkoloogia osa 3. versiooni järgi. Staadiumid grupeeriti TNM 
ja FIGO (Rahvusvaheline Günekoloogia ja Sünnitusabi Föderatsioon) klassi-
fikatsiooni alusel. Vanuserühmad moodustati vastavalt kasvajapaikme spetsii-
fikale. Andmed emakakehavähi kirurgilise ravi kohta pärinesid vähiteatistelt. 
Haigestumus- ja suremuskordajad arvutati kasutades aastakeskmist nais-
rahvastikku ja väljendati 100 000 inimaasta kohta. Vanusele kohandamiseks 
kasutati maailma standardrahvastikku. Kordajate modelleerimiseks ja aastase 
protsentuaalse muutuse ning 95% usaldusintervalli arvutamiseks kasutati join-
point regressioonanalüüsi. Haigestumust vaadeldi perioodil 1968–2016 ning 
suremust 1995–2016. Elulemusanalüüsi kaasati aastatel 1996–2016 diagnoosi-
tud esmasjuhud. 
Emakakaelavähi haigestumustrende analüüsiti täiendavalt vanus-periood-
kohort-mudeli abil. Arvutati eri sünnikohortide ja ajaperioodide suhteline risk. 
Emakakeha- ja emakakaelavähi suremuse analüüsimisel kasutati suremus-
kordajate korrigeerimist võimalike vigade suhtes, mis võivad tuleneda surma-
põhjuse valest kodeerimisest. Vead võivad esineda juhul, kui korrektse paikme-
spetsiifilise koodi asemel märgitakse surma põhjusena täpsustamata emaka-
kehavähk.  
Elulemusanalüüsi jaoks jälgiti patsientide elustaatust kuni 31. detsembrini 
2016, linkides vähiregistri andmed isikukoodi alusel Rahvastikuregistri andme-
tega. Isiku surma või riigist lahkumise korral saadi teada vastav kuupäev. 
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Suhteline elulemusmäär koos 95% usaldusintervalliga saadi tegeliku elulemuse 
jagamisel eeldatava elulemusega. Viimane leiti vastavalt Ederer II meetodile 
kasutades naisrahvastiku elutabeleid. Lahangul diagnoositud ja ainult surma-
tunnistuse juhud jäeti elulemusanalüüsist välja. Varasemate perioodide puhul 
kasutati suhtelise elulemusmäära arvutamiseks kohort-analüüsi, hilisemate 
perioodide puhul, mil kohordid polnud veel läbinud viieaastast jälgimisperioodi, 
kasutati periood-analüüsi. Vanusele kohandatud elulemusmäärade arvutamiseks 
kasutati rahvusvahelisi standardeid.  
 
Tulemused ja arutelu 
Kokku diagnoositi aastatel 1996–2016 Eestis 12 142 günekoloogilise pahaloo-
mulise kasvaja esmasjuhtu. Kõige sagedasem günekoloogiline pahaloomuline 
kasvaja oli sel perioodil emakakehavähk, mis moodustas 35% kõikidest juhtu-
dest. Kõige vähem esines häbeme- ja tupevähi juhte (6%). 20% kõikidest juhtu-
dest diagnoositi alla 50-aastastel naistel. Üle 80-aastaste naiste osakaal suurenes 
uuringuperioodi vältel 8%-lt 14%-le. 
Emakakehavähi haigestumus tõusis uuritud perioodil oluliselt, tingituna I 
tüüpi kasvajate haigestumuse suurenemisest. See omakorda on seostatav üle-
kaalulisuse ja rasvumise tõusuga rahvastikus. Korrigeeritud suremustrend oli 
stabiilne. I tüüpi emakakehavähk avastatakse sageli varases staadiumis, mil 
ravitulemused on head. Selle kasvajatüübi puhul on leitud, et 40% patsientidest 
sureb pigem kaasuva kardiovaskulaarse haiguse tõttu, mitte kasvajast tingitud 
põhjustel. Emakakehavähi viie aasta suhteline elulemus on oluliselt paranenud, 
ulatudes viimasel perioodil 78%-ni, mis jääb siiski alla Põhjamaades ja USA-s 
saavutatud tulemustele. Elulemus paranes enim eakatel patsientidel ja IV staa-
diumi puhul. Samaaegselt suurenes oluliselt kirurgiliselt ravitud patsientide osa-
kaal, mis on tõenäoliselt seotud kaasuvate haiguste tõhusama käsitluse ja vähe-
invasiivsete kirurgiliste meetodite arenguga. Võttes arvesse haigestumus- ja 
elulemustrende, viitab suremuskordajate püsimine samal tasemel võimalikele 
ebatäpsustele surmapõhjuste määramisel. 
Emakakaelavähi haigestumus on oluliselt tõusnud. Haigestumuse tõusu võis 
täheldada kõikides vanuserühmades, välja arvatud üle 70-aastaste naiste hulgas, 
ning nii lamerakuliste kui ka adenokartsinoomide puhul. Vanus-periood-kohort-
mudeli analüüsist selgus, et kõige madalam risk haigestuda emakakaelavähki on 
1940. aastatel sündinud naistel ja risk suureneb ühtlaselt kõikides hilisemates 
sünnikohortides. Perioodi-efekt oli stabiilne, millest järeldub, et alates 1970. 
aastatest ei ole toimunud olulisi ennetustegevusi, mis vähendaksid emakakaela-
vähi haigestumust. Olulise negatiivse leiuna ilmnes staadiumijaotuse nihe 
kaugelearenenud kasvajate suunas. Aastatel 2010–2014 diagnoositi I staadiumis 
35% juhtudest ning III ja IV staadiumis kokku 42% juhtudest. Hästi toimiva 
sõeluuringuga riikides ulatub I staadiumis diagnoositud juhtude osakaal üle 
60%. Viie aasta suhteline elulemus on viimastel aastatel jäänud samale tasemele 
(66%). Elulemuse tulemuste stabiliseerumist saab seostada hilisema staadiu-
miga diagnoosimisel ja kiiritusravi piiratud kättesaadavusega. Uuringu tulemus-
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test järeldub Eestis alates 2006. aastast läbi viidava emakakaelavähi sõeluuringu 
ebaefektiivsus.  
Munasarjavähi üldine haigestumus on olnud kogu vaadeldud perioodi vältel 
stabiilne, samuti kõikides vanuserühmades. Arvestades sagedast suukaudsete 
rasedusvastaste vahendite kasutust ning suurt sünnitajate arvu 1990-ndate 
aastate alguses, võib edaspidi eeldada pigem haigestumuse langust. Suremus on 
uuringuperioodil oluliselt langenud, eriti 50–59- ja 60–69-aastaste naiste hulgas. 
Oluliselt on tõusnud munasarjavähi viie aasta suhteline elulemus, ulatudes 
perioodil 2010–2016 44%-ni. Elulemuse tõus oli täheldatav kõikides vanuse-
rühmades ja kõikide staadiumite puhul. Eesti elulemusmäär uuringu viimasel 
perioodil on võrreldav riikidega, kus vähiravi on väga kõrgel tasemel. Uuringu-
tulemusi saab seostada vähiravi parema kvaliteedi ja kättesaadavusega Eestis. 
Häbeme- ja tupevähi haigestumus on olnud stabiilne, sh nii nooremate ja 
vanemate naiste seas. Samuti on püsinud muutumatuna nende kasvajate sure-
mus. Häbeme- ja tupevähi viie aasta suhteline elulemus on paranenud ja jõud-
nud 61%-ni, kuid viimasel uuringuperioodil on jäänud samaks. Uuringu tulemu-
sed näitavad, et Eestis ei esine Lääne-Euroopale iseloomulikku sagedasemat 
nooremate naiste haigestumuse trendi, mis võib olla seotud vähema HPV 
levikuga rahvastikus. 
 
Järeldused 
Uurimistöö annab esmakordselt tervikliku ülevaate günekoloogiliste kasvajate 
pikaajalistest haigestumuse, suremuse ja elulemuse trendidest Eestis. Trende on 
mõjutanud Eesti ühiskonnas aset leidnud sotsiaalsed ja tervishoiukorralduslikud 
muutused.  
1. Emakakehavähi haigestumus on tõusnud, peamiselt tingituna I tüüpi 
kasvajate haigestumuse tõusust. Suremus on olnud stabiilne. Emaka-
kehavähi elulemus on märkimisväärselt paranenud, mis on tõenäoliselt 
seotud oluliselt sagenenud kirurgilise raviga kõikides vanuserühmades 
ja staadiumites.  
2. Emakakaelavähi haigestumus suurenes uuringuperioodil oluliselt. 
Haigestumustrend on tingitud riski suurenemisest rahvastikus, mida ei 
ole tasakaalustanud tõhus ennetustegevus. Emakakaelavähi suremus 
püsis kõrgel tasemel. Elulemus on küll paranenud, kuid I staadiumis 
diagnoositud juhtude osakaalu langus ning vanemaealiste osakaalu tõus 
ei ole kooskõlas sõeluuringu oodatavate tulemustega. Võib järeldada, et 
emakakaelavähi sõeluuring on seni olnud ebaefektiivne. 
3. Munasarjavähi suremus ja elulemus on uuritud perioodi jooksul näida-
nud olulist positiivset trendi. Suremuse langus ja elulemuse pikenemine 
on toimunud vaatamata vanemaealiste ja enam levinud staadiumiga 
juhtude osakaalu suurenemisele.  
4. Häbeme- ja tupevähi haigestumus on püsinud uuringuperioodi vältel 
stabiilsena nii nooremas kui vanemas vanuserühmas. Elulemus on 
mõnevõrra paranenud. 
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Praktilised soovitused 
Uuringu tulemused näitavad vajadust muutuste läbiviimiseks tervishoiukorral-
duses ja tervislike eluviiside suuremaks tähtsustamiseks ühiskonnas, vältimaks 
naiste enneaegseid surmasid tulevikus. Vajalik on teadlikkuse tõstmine üle-
kaalust kui emakakehavähi peamisest riskitegurist. Elulemuse parandamiseks 
tuleb pöörata tähelepanu kaasuvate haiguste ennetamisele ja ravile. Emaka-
kaelavähi vähieelsete seisundite ja varajaste kasvajate diagnoosimise tõhusta-
miseks tuleb tagada riikliku sõeluuringu kvaliteet, kaasata uuringusse ravikind-
lustamata naised ning kaaluda HPV-DNA määramise lisamist sõeluuringu 
kavasse. Rõhutada ja selgitada tuleb tüdrukute vaktsineerimise tähtsust ning 
kaaluda poiste kaasamist vaktsineerimiskavasse. Munasarjavähi suremuse 
vähendamiseks tuleb järgida rahvusvahelisi ravijuhiseid, arendada personaalset 
meditsiini ja võimaldada selle kättesaadavust. Häbeme- ja tupevähi varaseks 
avastamiseks tuleb rõhutada korrapäraste günekoloogiliste läbivaatuste olu-
lisust. 
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